Document:

COLLABORATION
      AND LICENSE AGREEMENT

     

    by
      and between

     

    ROSETTA
      GENOMICS, LTD.

     

    and

     

    US
      GENOMICS, INC.

     

    May
      12, 2006

    

    

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    COLLABORATION
      AND LICENSE AGREEMENT

    

    

    This
      COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of May
      12, 2006, by and between Rosetta Genomics, Ltd., a corporation organized under
      the country of Israel having an address of 10 Plaut Street, Science Park,
      Rehovot, Israel (“Rosetta Genomics”) and US Genomics, Inc., a Delaware
      corporation having an address of 12 Gill Street. Suite 4700, Woburn, MA 01801
      (“US Genomics”). Each of US Genomics and Rosetta Genomics is sometimes referred
      to individually herein as a “Party” and collectively as the
“Parties.”

     

    WHEREAS,
      Rosetta Genomics is in the business of developing confidential and proprietary
      technology relating to the detection of biomarkers based on miRNA for Diagnosis
      of various diseases, including without any limitation Lung Cancer;
      and

     

    WHEREAS,
      US Genomics is in the business of developing and commercializing instruments
      and
      related reagents for the detection of molecules, including the development
      of
      the US Genomics Platform; and

     

    WHEREAS,
      Rosetta Genomics and US Genomics desire to enter into a collaboration for the
      purpose of jointly developing the Products and the Services; and

     

    WHEREAS,
      Rosetta Genomics wishes to acquire, and US Genomics has agreed to supply to
      Rosetta Genomics, the US Genomics Platform and reagent kits for use thereon
      for
      the purpose of researching, developing and commercializing the Products and
      the
      Services; and

     

    WHEREAS,
      US Genomics has agreed to non-exclusively license Rosetta Genomics under the
      US
      Genomics Know How and the US Genomics Patent Rights the right to develop and
      commercialize the Products and the Services on the terms set forth
      herein;

     

    NOW,
      THEREFORE, in consideration of the mutual covenants contained herein, and for
      other good and valuable consideration, the Parties hereto, intending to be
      legally bound, hereby agree as follows:

     

    ARTICLE
      I

     

    DEFINITIONS

     

    Unless
      specifically set forth to the contrary herein, the following terms, whether
      used
      in the singular or plural, shall have the respective meanings set forth
      below:

     

    
      	1.1.   
               	
              “Affiliate”
                of a Party or other entity shall mean any entity that, directly or
                indirectly, is controlled by, controls, or is under common control
                with
                such Party including (i) any corporation or business entity of which
                at
                least fifty percent (50%) of the securities or other ownership interests
                representing the equity or right to receive profits, the voting stock,
                general partnership interest or power to direct the affairs of such
                entity, are owned, controlled or held, directly or indirectly, by
                a Party
                or such entity; (ii) any corporation or business entity which, directly
                or
                indirectly, owns, controls or holds at least fifty percent (50%)
                of the
                securities or other ownership interests representing the equity or
                right
                to receive profits, voting stock, general partnership interest or
                power to
                direct the affairs of, a Party or such entity; or (iii) any corporation
                or
                business entity of which a Party or such entity has the right to
                acquire,
                directly or indirectly, at least fifty percent (50%) of the securities
                or
                other ownership interests representing the equity or right to receive
                profits, voting stock, general partnership interest or power to direct
                the
                affairs, thereof.

            

    

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	1.2.  
                	
              “Business
                Day”
                shall mean any day that is not a Saturday or a Sunday or a day on
                which
                the New York Stock Exchange or the Tel Aviv Stock Exchange is
                closed.

            

    

     

    
      	1.3.  
                	
              “Calendar
                Quarter”
                shall mean the respective periods of three (3) consecutive calendar
                months
                ending on March 31, June 30, September 30 and December
                31.

            

    

     

    
      	1.4.   
               	
              “Calendar
                Year”
                shall mean each successive period of twelve (12) months commencing
                on
                January 1 and ending on December
                31.

            

    

     

    
      	1.5.  
                	
              “Customers”
                shall mean patients, hospitals, physicians, medical institutions,
                health
                funds, pharmacies and other retailers, provided that they are not
                an
                Affiliate of Rosetta Genomics and other purchasers of the Products
                other
                than for resale.

            

    

     

    
      	1.6.   
               	
              “Development
                Plan”
                shall mean the plan to develop the Products and Services attached
                hereto
                as Exhibit A.

            

    

     

    
      	1.7.   
               	
              “Early
                Detection”
                means the determination of the presence of a disease prior to the
                appearance of symptoms.

            

    

     

    
      	1.8.   
               	
              “Effective
                Date”
                shall mean the date first above
                written.

            

    

     

    
      	1.9.   
               	
              “FDA”
                shall mean the United States Food and Drug Administration and any
                successor agency having substantially the same functions and any
                corresponding or successor regulatory authority in any other jurisdiction
                if the context so indicates.

            

    

     

    
      	1.10.   
               	
              “Field”
                shall mean Early Detection of Lung Cancer based on detection of microRNA
                markers of Lung Cancer tumors in sputum and/or
                blood.

            

    

     

    
      	1.11.   
               	
              “First
                Commercial Sale”
                shall mean the first for-profit sale of a Product or a Service by
                Rosetta
                Genomics or its Affiliates in any country in the Territory, for end
                use or
                consumption (including sales to a distributor or similar agent);
                provided,
                that, any sale to an Affiliate or Sublicensee will not constitute
                a First
                Commercial Sale unless the Affiliate or Sublicensee is the last entity
                in
                the distribution chain of the Product or
                Service.

            

    

     

    
      	1.12.  
                	
              “GAAP”
                means generally accepted accounting principles in the United
                States.

            

    

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	1.13.  
                	
              “Improvement”
                shall mean any and all improvements and enhancements, patentable
                or
                otherwise, related to the Product, Services, US Genomics Platform
                or US
                Genomics proprietary reagents including, without limitation, in the
                manufacture, formulation, ingredients, preparation, presentation,
                means of
                delivery or administration, indication, use or packaging of the Product,
                Services, US Genomics Platform or US Genomics proprietary
                reagents.

            

    

     

    
      	1.14.   
               	
              “Information
                and Inventions”
                shall mean all discoveries, Improvements, processes, formulas, data,
                inventions, know-how and trade secrets, patentable or otherwise arising
                from the activities of the Parties under this
                Agreement.

            

    

     

    
      	1.15.  
                	
              “LIBOR”
                shall mean, with respect to any interest period, the rate per annum,
                reported by JP Morgan Chase or any successor thereto, at which deposits
                in
                United States dollars are offered to prime commercial banks in the
                London
                interbank market at approximately 11:00 a.m., New York City time
                on the
                Business Day immediately preceding the commencement of such interest
                period.

            

    

     

    
      	1.16.   
               	
              “Lung
                Cancer”
                shall mean the development of malignant neoplasia of the lung and
                associated disregulation of genes within the lung
                tissue.

            

    

     

    
      	1.17.   
               	
              “Net
                Sales”
                shall mean the aggregate gross amount invoiced with respect to Services
                or
                Products by Rosetta Genomics or its Affiliates or its Sublicensees
                to
                Customers, after deducting (if not previously deducted from the amount
                invoiced):

            

    

     

    
      	(i)          
               	
              quantity
                and/or cash discounts directly related to the sale of the
                Product;

            

    

     

    
      	(ii)           	
              customs
                duties, VAT or any other sales taxes or levies to the extent applicable
                to
                the sale or export of Products or Services and not collected separately
                from the counterparty to the sale;

            

    

     

    
      	(iii)        
               	
              recalls,
                credits and allowances on account of returned or rejected products,
                including, but not limited to, allowance for breakage or
                spoilage;

            

    

     

    
      	(iv)       
               	
              payments
                paid in connection with transporting, packaging and insuring the
                Products
                and appearing separately on invoices;
                and

            

    

     

    
      	(v)        
               	
              amounts
                not actually collected.

            

    

     

    Notwithstanding
      the foregoing, sales or other transfers between Rosetta Genomics and its
      Affiliates shall be excluded from the computation of Net Sales and no royalty
      payments shall be payable on such sales or transfers except where such
      Affiliates are end users, but Net Sales shall include the subsequent sales
      to
      Customers by such Affiliates. Sales to wholesalers or distributors shall be
      included in Net Sales and sales by a wholesaler or distributor shall not be
      included in Net Sales.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	1.18.   
               	
              “Other
                US Genomics Patented Product”
                shall mean any product or service sold for use in the Field whose
                composition of matter or use in the Field is covered by one or more
                Valid
                Claims, where the Early Detection is made using a system other than
                the US
                Genomics Platform.

            

    

     

    
      	1.19.   
               	
              “Product”
                shall mean a US Genomics Based Product or an Other US Genomics Patented
                Product. For purposes of clarity, (x) Products shall not include
                (a) the
                US Genomics Platform or any modification or improvement thereof or
                (b) any
                “next generation” US Genomics Platform and (y) all Products shall be
                listed in Schedule 1.18 attached hereto, as updated from time to
                time by
                Rosetta Genomics and US Genomics during the
                Term.

            

    

     

    
      	1.20.   
               	
              “Proprietary
                Information”
                shall mean any and all scientific, clinical, regulatory, marketing,
                financial and commercial information or data, whether communicated
                in
                writing, orally or by any other means, which is provided by one Party
                to
                the other Party in connection with this Agreement. For clarity, any
                microRNA sequence disclosed by Rosetta Genomics to US Genomics shall
                be
                Proprietary Information of Rosetta Genomics, to the extent the foregoing
                do not fall within the exceptions described in clauses (i) through
                (iv) of
                Section 4.1.

            

    

     

    
      	1.21.  
                	
              “Proprietary
                Materials”
                shall mean any tangible chemical, biological or physical research
                materials that are furnished by or on behalf of the Transferring
                Party to
                the Recipient Party in connection with this Agreement, regardless
                of
                whether such materials are specifically designated as proprietary
                by the
                Transferring Party.

            

    

     

    
      	1.22.  
                	
              “Regulatory
                Requirements”
                shall mean current applicable manufacturing and other requirements
                for
                Products as defined in regulations promulgated by the FDA and, for
                Products intended for shipment to any country other than the United
                States, as defined in regulations promulgated by the corresponding
                regulatory authority in such
                country.

            

    

     

    
      	1.23.  
                	
              “Rosetta
                Genomics Know-How”
                shall mean Rosetta Genomics Information and Inventions, and any and
                all
                other information and materials, including but not limited to,
                discoveries, information, improvements, processes, formulas, data,
                inventions, know-how and trade secrets, patentable or otherwise,
                which in
                all cases

            

    

     

    
      	(i)         
                	
              relate
                to the Products or the Services;
                and

            

    

     

    
      	(ii)         
               	
              are
                in Rosetta Genomics’ possession or control as of and after the date hereof
                and as to which Rosetta Genomics has the right to license or sublicense
                to
                third parties, and are necessary or useful to Rosetta Genomics in
                connection with the rights granted and activities contemplated under
                this
                Agreement.

            

    

     

    Such
      know-how shall include, without limitation, all chemical, pharmaceutical,
      toxicological, preclinical, clinical, assay control, manufacturing, regulatory,
      and any other information used or useful for the development, and/or regulatory
      approval of Products or Services.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	1.24.   
               	
              “Rosetta
                Genomics Patent Rights”
                shall mean United States and foreign patents and patent applications
                (which shall be deemed to include certificates of invention and
                applications for certificates of invention) which as of the Effective
                Date
                or at any time during the term of this
                Agreement

            

    

     

    
      	(i)         
                	
              are
                owned by Rosetta Genomics or which Rosetta Genomics through license
                or
                otherwise has or acquires rights (and is not prohibited from sublicensing
                to US Genomics); and

            

    

     

    
      	(ii)         
               	
              relate
                in any way to Products, Services or any Improvement or otherwise
                relate to
                Information and Inventions, including all certificates of invention,
                divisions, continuations, continuations-in-part, reissues, renewals,
                extensions, supplementary protection certificates or the like of
                any such
                patents and current and future patent applications, and any counterparts
                thereof which may be filed in other countries. Any Rosetta Genomics
                Patent
                Rights and any subsequent changes thereto shall be attached hereto
                as
                Exhibit C, provided, however, that the failure to include the then
                current
                Rosetta Genomics Patent Rights in Exhibit C from time to time shall
                not
                affect the Parties’ respective rights and obligations under this
                Agreement.

            

    

     

    
      	1.25.  
                	
              “Royalty
                Year”
                shall mean (i) for the year in which the First Commercial Sale occurs,
                the
                period commencing with the date of such First Commercial Sale and
                expiring
                on the last day of the Calendar Quarter in which the twelfth (12th)
                month
                following the date of the First Commercial Sale occurs and (ii) for
                each
                subsequent year, each successive twelve (12) month
                period.

            

    

     

    
      	1.26.  
                	
              “SEC”
                means the United States Securities and Exchange
                Commission.

            

    

     

    
      	1.27.   
               	
              “Services”
                means any service performed using the US Genomics Platform in the
                Field.

            

    

     

    
      	1.28.   
               	
              “Sublicense”
                shall mean a sublicense by Rosetta Genomics to a Third Party granted
                in
                accordance with Section 2.3 of this
                Agreement.

            

    

     

    
      	1.29.   
               	
              “Sublicense
                Income”
                shall mean all license fees and milestone payments and other payments
                paid
                by a Sublicensee to Rosetta Genomics in consideration of the grant
                of a
                Sublicense to such Sublicensee, excluding royalties, equity investments
                in
                Rosetta Genomics at fair market value, research funding paid to Rosetta
                Genomics at cost or loans to Rosetta Genomics from the Sublicensee
                on
                commercial arms length terms.

            

    

     

    
      	1.30.  
                	
              “Sublicensee”
                shall mean a sublicensee who was granted a Sublicense from Rosetta
                Genomics.

            

    

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	1.31.   
               	
              “Territory”
                shall mean all the countries in the
                world.

            

    

     

    
      	1.32.   
               	
              “US
                Genomics Based Product”
                shall mean any product or service sold for use in the Field whose
                manufacture, use or sale in the Field is covered by one or more Valid
                Claims, where the Early Detection is made using the US Genomics
                Platform.

            

    

     

    
      	1.33.  
                	
              “US
                Genomics Know-How”
                shall mean any and all US Genomics Information and Inventions, and
                all
                other information and materials, including but not limited to,
                discoveries, information, Improvements, processes, formulas, data,
                inventions, know-how and trade secrets, patentable or otherwise,
                which in
                all cases

            

    

     

    
      	(i)         
                	
              relate
                to Products, Services or the use of the US Genomics Platform in the
                Field;
                and

            

    

     

    
      	(ii)        
                	
              are
                in US Genomics’ possession or control as of and after the date hereof and
                as to which US Genomics has the right to license or sublicense to
                third
                parties, and are necessary or useful to Rosetta Genomics in connection
                with the rights granted and activities contemplated under this
                Agreement.

            

    

     

    Such
      know-how shall include, without limitation, all biological, chemical,
      pharmaceutical, toxicological, preclinical, clinical, assay control, regulatory,
      and any other information used or useful for the development, manufacturing
      and/or regulatory approval of Products or Services.

     

    
      	1.34.  
                	
              “US
                Genomics Patent Rights”
                shall mean United States and foreign patents and patent applications
                (which shall be deemed to include certificates of invention and
                applications for certificates of invention) which as of the Effective
                Date
                or at any time during the term of this
                Agreement

            

    

     

    
      	(i)         
                	
              are
                owned by US Genomics or jointly owned by US Genomics and Rosetta
                Genomics
                or which US Genomics through license or otherwise has or acquires
                rights
                (and is not prohibited from sublicensing to Rosetta Genomics);
                and

            

    

     

    
      	(ii)         
               	
              relate
                in any way to the Products, Services, the use of the US Genomics
                Platform
                in the Field and/or any Improvement, or otherwise relate to Information
                and Inventions, including all certificates of invention, divisions,
                continuations, continuations-in-part, reissues, renewals, extensions,
                supplementary protection certificates or the like of any such patents
                and
                current and future patent applications, and any counterparts thereof
                which
                may be filed in other countries, and additional patents or patent
                applications which arise as a result of research and development
                of the
                Products and Services under this Agreement. US Genomics Patent Rights,
                as
                of the Effective Date, consist of the patents and patent applications
                listed on Exhibit B hereto. Any subsequent US Genomics Patent Rights
                and
                any changes to any US Genomics Patent Rights shall be added to Exhibit
                B,
                provided, however, that the failure to include the then current US
                Genomics Patent Rights in Exhibit B from time to time shall not affect
                the
                Parties’ respective rights and obligations under this
                Agreement.

            

    

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	1.35.   
               	
              “US
                Genomics Platform”
                means the platform developed by US Genomics for the detection and
                quantitation of single molecules.

            

    

     

    
      	1.36.  
                	
              “Third
                Party”
                shall mean a person or entity who or which is neither a Party nor
                an
                Affiliate of a Party.

            

    

     

    
      	1.37.  
                	
              “Valid
                Claim”
                means a claim of an issued and unexpired patent or patent application
                included within the US Genomics Patent Rights, which has not been
                revoked
                or held unenforceable or invalid by a decision of a court or other
                governmental agency of competent jurisdiction, unappealable or for
                which
                an appeal has not been filed within the time allowed for appeal,
                and which
                has not been disclaimed, denied or admitted to be invalid or unenforceable
                through reissue or disclaimer or
                otherwise.

            

    

     

    
      	1.38.   
               	
              “Additional
                Definitions”
                In addition, each of the following definitions shall have the respective
                meanings set forth in the section of this Agreement indicated
                below:

            

    

     

    
      	
              Definition

               

            	
              Section

               

            
	
              Claims

            	
              10.1

            
	 	 
	
              Disputed
                Matter

            	
              11.6

            
	 	 
	
              Indemnified
                Party

            	
              10.1

            
	 	 
	
              Indemnifying
                Party

            	
              10.2

            
	 	 
	
              Joint
                Information and Inventions

            	
              3.6(iii)

            
	 	 
	
              Losses

            	
              10.1.1

            
	 	 
	
              Quarterly
                Report

            	
              5.2

            
	 	 
	
              Recipient
                Party

            	
              3.1(v)

            
	 	 
	
              Rosetta
                Genomics Information and Inventions

            	
              3.6(ii)

            
	 	 
	
              Transferring
                Party

            	
              3.1(v)

            
	 	 
	
              US
                Genomics Information and Inventions

            	
              3.6(i)

            

    

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    ARTICLE
      II

     

    LICENSE;
      SUBLICENSES

     

    
      	2.1.  	
              License
                Grant.

            

    

     

    
      	2.1.1     
                	
              US
                Genomics hereby grants to Rosetta Genomics a non-exclusive, worldwide
                license, under the US Genomics Patent Rights and the US Genomics
                Know How,
                and the US Genomics Improvements (as such term is defined under Section
                3.5.(i)), including the right to grant sublicenses on the terms set
                forth
                herein, to (a) use the US Genomics Platform for internal research
                for the
                purpose of developing Products and Services, and (b) to develop,
                use,
                import, offer for sale, market, commercialize, manufacture, distribute
                and
                sell the Products and the Services in the Territory, both solely
                for the
                Field.

            

    

     

    
      	2.1.2      
               	
              US
                Genomics hereby grants to Rosetta Genomics a worldwide, royalty-free,
                paid-up, non-exclusive license, without the right to sublicense,
                under the
                US Genomics Know-How and the US Genomics Patent Rights solely as
                required
                in order for Rosetta Genomics to carry out its obligations and
                responsibilities under the Development
                Plan.

            

    

     

    
      	2.2.  	
              US
                Genomics hereby grants to Rosetta Genomics a worldwide, royalty-free,
                paid-up, non-exclusive license, with the right to grant sublicenses,
                under
                the US Genomics Information and Inventions solely to the extent that
                the
                US Genomics Information and Inventions constitute an improvement
                to or
                modification of Rosetta Genomics Know-Flow or Rosetta Genomics Patent
                Rights for use by Rosetta Genomics solely in connection with the
                practice
                of the Rosetta Genomics Know-flow and Rosetta Genomics Patent Rights.
                License Grant by Rosetta Genomics

            

    

     

    
      	2.2.1     
                	
              Rosetta
                Genomics hereby grants to US Genomics a worldwide, royalty-free,
                paid-up,
                non-exclusive license, without the right to sublicense, under the
                Rosetta
                Genomics Know-How, the Rosetta Genomics Patent Rights and the Rosetta
                Genomics Improvement (as such term is defined under section 3.5(ii)),
                solely as required in order for US Genomics to carry out its obligations
                and responsibilities under the Development
                Plan.

            

    

     

    
      	2.2.2      
               	
              Rosetta
                Genomics hereby grants to US Genomics a worldwide, royalty-free,
                paid-up,
                non-exclusive license, with the right to grant sublicenses, under
                the
                Rosetta Genomics Information and Inventions solely to the extent
                that the
                Rosetta Genomics Information and Inventions constitute an improvement
                to
                or modification of US Genomics Know-How or US Genomics Patent Rights
                for
                use by US Genomics solely in connection with the practice of the
                US
                Genomics Know-How and US Genomics Patent
                Rights.

            

    

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	2.3.  	
              Retained
                Rights.
                Except as specifically set forth herein, Rosetta Genomics is not
                granted
                any other license by implication or otherwise. US Genomics shall
                retain
                the right to use the US Genomics Know-How and US Genomics Patent
                Rights
                for all purposes inside or outside the
                Field.

            

    

     

    
      	2.3.1      
               	
              Except
                as specifically set forth herein, US Genomics is not granted any
                other
                license by implication or otherwise. Rosetta Genomics shall retain
                the
                right to use the Rosetta Genomics Know-How and Rosetta Genomics Patent
                Rights for all purposes inside or outside the
                Field.

            

    

     

    
      	2.4.  	
              Sublicenses.
                Subject to compliance with the provisions of this Agreement, Rosetta
                Genomics shall have the right to grant sublicenses to any Third Party
                under the US Genomics Know How and US Genomics Patent Rights in the
                Field
                in the Territory, with the consent of US Genomics, such consent not
                to be
                unreasonably withheld. Any grant by Rosetta Genomics of a Sublicense
                shall
                be consistent with the terms of this
                Agreement.

            

    

     

    ARTICLE
      III

     

    DEVELOPMENT
      AND COMMERCIALIZATION

     

    
      	3.1.  	
              Diligence;
                Development and
                Commercialization

            

    

     

    
      	(i)          
               	
              Mutual
                Responsibilities of the Parties.
                The initial Development Plan covering the activities to be carried
                out by
                the Parties under this Agreement is attached hereto as Exhibit
                A.
                The parties shall use commercially reasonable efforts to complete
                the
                Development Plan activities on the timelines specified therein. The
                Parties may, by mutual agreement, make adjustments and amendments
                to the
                Development Plan as reasonably required during the term of this Agreement,
                which adjustments and amendments shall be attached as an addendum
                to
                Exhibit
                A.
                Each adjustment and amendment to the Development Plan shall be in
                writing
                and shall: (a) set forth (i) the activities to be performed with
                reasonable specificity and the anticipated timeline for such activities,
                provided however that such timeline shall not obligate the Parties,
                and
                (ii) the Party that shall be responsible for performing such activities;
                and (b) be consistent with the terms of this Agreement. Each Party
                agrees
                to use commercially reasonable efforts to perform its respective
                activities under the Development Plan, with the goal of developing
                Products and Services. Without limiting the foregoing, each Party
                shall
                (A) commit such scientific resources, including, but not limited
                to
                consultants, facilities, equipment, and Proprietary Materials, as
                are
                reasonably necessary to achieve the objectives of the Development
                Plan and
                (B) perform its obligations under the Development Plan in good scientific
                manner and in compliance in all material respects with all applicable
                laws.

            

    

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	(ii)         
               	
              Rosetta
                Genomics’ Responsibilities.
                In addition to the other obligations of Rosetta Genomics set forth
                in this
                Agreement, Rosetta Genomics shall be responsible
                to:

            

    

     

    
      	(1)        
                	
              Obtain
                all clinical samples required in the course of the Development
                Plan;

            

    

     

    
      	(2)         
               	
              Undertake
                the experimental work required under Phase Ia, Phase Ib and Phase
                II of
                the Development Plan, either by itself or, through a sublicensee
                or a
                sub-contractor;

            

    

     

    
      	(3)         
               	
              Provide
                US Genomics with purified RNA for use in Phase Ic and Phase 2 of
                the
                Development Plan; and

            

    

     

    
      	(4)        
                	
              Fund
                and perform Phase III of the Development Plan on the US Genomics
                Platform.
                Rosetta Genomics may, negotiate third party support for some or all
                of
                Phase III and any subsequent clinical/regulatory
                development.

            

    

     

    
      	(iii)  	
              US
                Genomics’ Responsibilities.
                In addition to the other obligations of US Genomics set forth in
                this
                Agreement, US Genomics shall be responsible
                to:

            

    

     

    
      	(1)         
               	
              Undertake
                associated experimental work during all clinical phases as set forth
                in
                the Development Plan;

            

    

     

    
      	(2)        
                	
              Fund
                and support any required placement of instruments and reagents during
                the
                Development Plan including the supply and maintenance of [***] US
                Genomics
                Platform together with reagents necessary for [***] samples in Phases
                I
                and II, and [***] additional US Genomics Platforms together with
                reagents
                necessary for [***] samples in Phase III, with all US Genomics Platforms
                being provided and supported at a facility mutually agreed upon by
                both
                Parties ; and

            

    

     

    
      	(3)       
                	
              Fund
                and perform any commercially reasonable platform development work
                necessary for the development of the
                project.

            

    

     

    
      	(iv)  	
              Cooperation.
                The Parties acknowledge that the implementation of the Development
                Plan
                will require cooperation of the Parties and, in connection therewith,
                agree to cooperate in the performance of the Development Plan and,
                subject
                to the terms of this Agreement and any confidentiality obligations
                to
                Third Parties, shall exchange in a timely fashion such data, information
                and materials as are reasonably necessary for the other Party to
                perform
                its obligations under the Development
                Plan.

            

    

     

    
      	(v)  	
              Records.
                Each Party shall maintain records of its activities under the Development
                Plan in sufficient detail, in good scientific manner and otherwise
                in a
                manner that reflects all work done and results achieved in the performance
                of the Development Plan. Without limiting the generality of this
                Section
                3.1(iii), each Party agrees to maintain a policy that requires its
                employees and consultants to record and maintain all data and information
                developed under the Development Plan in a manner designed to enable
                the
                Parties to use such records to establish the earliest date of invention
                or
                reduction to practice.

            

    

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	(vi)  	
              Reports
                and Data.
                Each Party shall keep the other Party regularly informed of the progress
                of the Development Plan. Without limiting the generality of the foregoing,
                the Parties shall, not less than once each Calendar Quarter during
                the
                Term (and more frequently if required to keep the other Party sufficiently
                informed), provide to the other Party (i) reports in reasonable detail
                regarding the status of each Party’s activities under the Development Plan
                and (ii) such supporting data and information as may be reasonably
                requested from time to time by the other Party regarding the Development
                Plan.

            

    

     

    
      	(vii)  	
              Supply
                of Proprietary Materials.
                From time to time during the Term, in addition to the supply of reagent
                kits as set forth in Section 3.1(iii), each Party (the “Transferring
                Party”) shall supply the other Party (the “Recipient Party”), at its sole
                expense, with Proprietary Materials of the Transferring Party for
                use in
                the Development Program as specified in the Development Plan. In
                connection therewith, each Recipient Party hereby agrees that (a)
                it shall
                not use such Proprietary Materials for any purpose other than exercising
                its rights or performing its obligations hereunder; (b) it shall
                use such
                Proprietary Materials only in compliance with all applicable laws;
                (c) it
                shall not transfer any such Proprietary Materials to any Third Party
                without the prior written consent of the Transferring Party, except
                as
                expressly permitted hereby; (d) the Recipient Party shall not acquire
                any
                right, title or interest in or to such Proprietary Materials as a
                result
                of such supply by the Transferring Party except as expressly set
                forth
                herein; and (e) upon the expiration or termination of the Term, the
                Recipient Party shall, if and as instructed by the Party, either
                destroy
                or return any such Proprietary Materials that are not the subject
                of the
                grant of a continuing license
                hereunder.

            

    

     

    
      	(viii)  	
              Expenses.
                Except as expressly set forth herein, each Party shall bear its own
                costs
                and expenses in the performance of the Development
                Plan.

            

    

     

    
      	3.2.  	
              Regulatory
                Matters.
                Rosetta Genomics shall own, control and retain primary legal
                responsibility for the preparation, filing and prosecution of all
                filings
                and regulatory applications required to obtain and maintain authorization
                to develop, sell and use Products and/or Services in the Field in
                the
                countries throughout the Territory. Rosetta Genomics shall provide
                to US
                Genomics all filings, material correspondence and other documentation
                in
                connection with such applications and authorization in sufficiently
                timely
                fashion to permit US Genomics to review and comment on such materials
                and
                shall reasonably consider any such comments. The Supply Agreement
                to be
                negotiated pursuant to Article IX will provide that US Genomics will
                comply with all regulatory requirements with respect to the manufacture
                of
                US Genomics Based Products and the US Genomics Platform, including,
                without limitation, the QSR/GMP requirements set forth in 21CFR Part
                820.

            

    

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	3.3.  	
              Trademark.
                Rosetta Genomics or any Sublicensee shall, as applicable and determined
                by
                Rosetta Genomics, select, own and maintain, at its expense, trademarks
                for
                all Products and Services.

            

    

     

    
      	3.4.  	
              Exchange
                of Information

            

    

     

    Each
      Party shall disclose to the other Party in English and in writing all Know-How
      of such Party not previously disclosed to the other Party that is necessary
      or
      useful for the conduct of the Development Plan and/or the commercialization
      of
      Products and the US Genomics Platform. Throughout the term of this Agreement,
      and in addition to the other communications required under this Agreement,
      each
      Party shall also promptly disclose to the other party in English and in writing
      on an ongoing basis all Know-How of such Party and other information developed
      in connection with the Parties’ activities under this Agreement. Throughout the
      term of this Agreement, and in addition to the other communications required
      under this Agreement, each Party shall promptly disclose to the other Party
      in
      English and in writing all Know-How of such Party and other information
      developed in connection with such Parties’ activities under this
      Agreement.

     

    
      	3.5.  	
              Information
                and Inventions.
                Ownership of Information and Inventions developed or invented, or
                which
                are discovered or which accrue in the course of or which arise or
                stem
                from the performance of research and development under this Agreement,
                and
                all patent and other intellectual property rights relating thereto
                shall
                be determined as follows:

            

    

     

    
      	(i)           
               	
              such
                Information and Inventions that are solely related to, improvements
                to or
                modifications of US Genomics Know-How or US Genomics Patent Rights
                shall
                be owned solely by US Genomics, (“US Genomics
                Improvements”);

            

    

     

    
      	(ii)          
               	
              such
                Information and Inventions that are solely related to, improvements
                to or
                modifications of Rosetta Genomics Know-How or Rosetta Genomics Patent
                Rights shall be owned solely by Rosetta Genomics (“Rosetta Genomics
                Improvements”);

            

    

     

    
      	(iii)         
               	
              such
                Information and Inventions that are not described in clauses (i)
                or (ii)
                above and that are developed or invented, or which accrue in the
                course of
                or which arise or stem from the performance of research and development
                under this Agreement solely by employees, agents, or consultants
                of US
                Genomics shall be owned solely by US Genomics (“US Genomics Information
                and Inventions”)

            

    

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	(iv)   
                     	
              such
                Information and Inventions that are not described in clauses (i)
                or (ii)
                above and that are developed or invented, or which accrue in the
                course of
                or which arise or stem from the performance of research and development
                under this Agreement solely by employees, agents, or consultants
                of
                Rosetta Genomics shall be owned solely by Rosetta Genomics (“Rosetta
                Genomics Information and
                Inventions”)

            

    

     

    
      	(v)    
                    	
              such
                Information and Inventions that are not described in clauses (i)
                or (ii)
                above and that are developed or invented, or which accrue in the
                course of
                or which arise or stem from the performance of research and development
                under this Agreement jointly by employees, agents or consultants
                of US
                Genomics and Rosetta Genomics shall be owned jointly by US Genomics
                and
                Rosetta Genomics; (“Joint Information and Inventions”), subject to the
                rights of, and the licenses granted to, each Party hereunder.
                Notwithstanding anything to the contrary contained herein or under
                applicable law, the Parties hereby agree that either Party may use
                or
                license or sublicense to Affiliates or third parties all or any portion
                of
                its interest in Joint Information and Inventions for any purposes
                outside
                the Field without the prior written consent of the other Party, without
                restriction and without the obligation to provide compensation to
                the
                other Party.

            

    

     

    Each
      Party shall promptly disclose to the other Party the development, making
      conception or reduction to practice of Information and Inventions, subject
      to
      the other provisions of this Agreement, and each Party shall execute and deliver
      any necessary assignments and other instruments and take any additional actions
      as may be requested by the other Party to effect the provisions of clauses
      (i)
      and (ii) of this Subsection.

     

    Inventorship
      shall be determined in accordance with United States law, and, notwithstanding
      any other provision of this Agreement, disputes regarding the treatment of
      Information and Inventions under this Section shall be resolved by an
      independent patent counsel mutually agreeable to the Parties, the costs of
      which
      shall be borne equally by the Parties.

     

    
      	3.6.  	
              Negotiation
                outside the Field.
                At the request of either Party, both Parties will negotiate in good
                faith
                with respect to a possible collaboration to develop products and
                services
                utilizing the US Genomics US Genomics Platform or a modification
                thereof
                for specific diseases outside the Field. Neither Party shall be obligated
                to enter into any such agreement with the
                other.

            

    

     

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    ARTICLE
      IV

     

    CONFIDENTIALITY
      AND PUBLICITY

     

    
      	4.1.  	
              Non-Disclosure
                and Non-Use Obligations

            

    

     

    All
      Proprietary Information disclosed by one Party to the other Party hereunder
      shall be maintained in confidence and shall not be disclosed to any Third Party
      or used for any purpose except as expressly permitted herein without the prior
      written consent of the Party that disclosed the Proprietary Information to
      the
      other Party. The foregoing non-disclosure and non-use obligations shall not
      apply to the extent that such Proprietary Information:

     

    
      	(i)         
                	
              is
                known by the receiving Party at the time of its receipt, and not
                through a
                prior disclosure by the disclosing Party, as documented by contemporaneous
                written records;

            

    

     

    
      	(ii)        
                	
              is
                in the public domain or knowledge;

            

    

     

    
      	(iii)       
                	
              is
                subsequently disclosed to a receiving Party by a Third Party who
                may
                lawfully do so and is not under an obligation of confidentiality
                to the
                disclosing Party; or

            

    

     

    
      	(iv)        
               	
              is
                developed by the receiving Party independently of Proprietary Information
                received from the other Party, as documented by contemporaneous research
                and development records.

            

    

     

    
      	4.2.  	
              Permitted
                Disclosure of Proprietary Information.

            

    

     

    Notwithstanding
      Section 4.1, a Party receiving Proprietary Information of another Party may
      disclose such Proprietary Information:

     

    
      	(i)           
               	
              to
                governmental or other regulatory agencies in order to obtain patents
                on
                Products or Services, or to gain approval to conduct clinical trials
                or to
                market Products and Services to the extent permitted hereunder, but
                such
                disclosure may be only to the extent reasonably necessary to obtain
                such
                patents or authorizations;

            

    

     

    
      	(ii)          
               	
              to
                its respective agents, consultants, Affiliates, sublicensees and/or
                other
                Third Parties for the research and development, manufacturing and/or
                marketing of Products or Services (or for such parties to determine
                their
                interests in performing such activities) on the condition that such
                Third
                Parties agree to be bound by the confidentiality obligations contained
                in
                this Agreement; or

            

    

     

    
      	(iii)        
                	
              if
                required to be disclosed by law or court order, provided that notice
                is
                promptly delivered to the disclosing Party in order to provide an
                opportunity to challenge or limit the disclosure obligations; provided,
                however,
                without limiting any of the foregoing, it is understood that either
                Party
                or its Affiliates may make disclosure of this Agreement and the terms
                hereof in any filings required by the SEC, may file this Agreement
                as an
                exhibit to any filing with the SEC and may distribute any such filing
                in
                the ordinary course of its business. However, to the maximum extent
                allowable by SEC rules and regulations, the Parties shall be obligated
                to
                maintain the confidentiality obligations set forth herein and shall
                redact
                any confidential information set forth in such filings as may be
                reasonably requested by the disclosing
                Party.

            

    

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	4.3.  	
              Publication.
                During the term of this Agreement, US Genomics and Rosetta Genomics
                each
                acknowledge the other Party’s interest in issuing press releases and
                publishing its results related to the Products and Services for marketing
                purposes and to obtain recognition within the scientific community
                and to
                advance the state of scientific knowledge. Each Party also recognizes
                the
                mutual interest in obtaining valid patent protection and in protecting
                business interests and trade secret information. Consequently, either
                Party, its employees or consultants wishing to make a publication
                shall
                deliver to the other Party a copy of the proposed written publication
                or
                an outline of the proposed oral disclosure at least thirty (30) days
                prior
                to submission for publication or presentation in the case of a publication
                or presentation and at least five (5) days prior to release in the
                case of
                a press release. The other Party shall have the right (a) to propose
                modifications to the publication, presentation or press release for
                scientific reason, patent reasons, trade secret reasons (including
                disclosure of Proprietary Information) or business reasons or (b)
                to
                request a reasonable delay in publication, presentation or issue
                of the
                press release in order to protect patentable information. If the
                other
                Party requests a delay, the publishing Party shall delay submission
                or
                presentation for a period of thirty (30) days (or five (5) days in
                the
                case of a press release) to enable patent applications protecting
                each
                Party’s rights in such information to be filed and the redaction of
                Proprietary Information. Upon expiration of such thirty (30) days
                or five
                (5) days, the publishing Party shall be free to proceed with the
                publication, presentation or issue of the press release, but may
                not
                include Proprietary Information of the other Party unless it is within
                an
                exception of Section 4.1(i) through 4.1(iv). If the other Party requests
                modifications to the publication, presentation or press release,
                the
                publishing Party shall edit such publication, presentation or press
                release to prevent disclosure of trade secret or Proprietary Information
                prior to submission of the publication or presentation or issue of
                the
                press release.

            

    

     

    ARTICLE
      V

     

    PAYMENTS,
      ROYALTIES AND REPORTS

     

    
      	5.1.  	
              Royalties
                to US Genomics

            

    

     

    
      	(i)            	
              Subject
                to the terms and conditions of this Agreement, and in consideration
                of the
                rights granted by US Genomics hereunder, Rosetta Genomics shall pay
                to US
                Genomics royalties in an amount equal to the following percentages
                of
                annual Net Sales by Rosetta Genomics or its Affiliates of any US
                Genomics
                Based Products and/or Services within the Field in the Territory
                in each
                Royalty Year:

            

    

     

    
      	
              Amount
                of Net Sales

               

            	
              Royalty
                Rate

               

            
	
              Up
                to and including US$[***] million

               

            	
              [***]%

               

            
	
              Above
                US$[***] million up to and including US$[***] million

               

            	
              [***]%

               

            
	
              Above
                US$[***] million

               

            	
              [***]%

               

            

    

    
       

      	(ii)       
               	
              Subject
                to the terms and conditions of this Agreement, and in consideration
                of the
                rights granted by US Genomics hereunder, Rosetta Genomics shall pay
                to US
                Genomics royalties in an amount equal to the following percentages
                of
                annual Net Sales by Rosetta Genomics or its Affiliates of any US
                Genomics
                Based Products and/or Services within the Field in the Territory
                in each
                Royalty Year

            

    

     

    
      	
              Amount
                of Net Sales

               

            	
              Royalty
                Rate

               

            
	
              Up
                to and including US$[***] million

               

            	
              [***]%

               

            
	
              Above
                US$[***] million up to and including US$[***] million

               

            	
              [***]%

               

            
	
              Above
                US$[***] million up to and including US$[***] million

               

            	
              [***]%

               

            
	
              Above
                US$[***] million

               

            	
              [***]%

               

            

    

     

    
      	(iii)    
                	
              Subject
                to the terms and conditions of this Agreement, and in consideration
                of the
                rights granted by US Genomics hereunder, Rosetta Genomics will pay US
                Genomics an amount equal to the following percentages of all royalties
                received from Sublicensees with respect to sale of US Genomics Based
                Products and/or Services by Sublicensees within the Field in the
                Territory
                in each Royalty Year:

            

    

     

    
      	
              Amount
                of Net Sales on which royalties are paid to

            	
              Percentage
                of

            
	
              Rosetta
                Genomics by Sublicensees

            	
              Sublicensee

            
	
               

            	
              Royalty
                to

            
	
               

            	
              Be
                paid to U.S

            
	
               

            	
              Genomics

            
	
              Up
                to and including US$[***] million

               

            	
              [***]%

               

            
	
              Above
                US$[***] million up to and including US$[***] million

               

            	
              [***]%

               

            
	
              Above
                US$[***] million

               

            	
              [***]%

               

            

    

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      
        	(iv)    
                  	
                Subject
                  to the terms and conditions of this Agreement, and in consideration
                  of the
                  rights granted by US Genomics hereunder, Rosetta Genomics will
                  pay US
                  Genomics an amount equal to the following percentages of all royalties
                  received from Sublicensees with respect to sale of Other US Genomics
                  Patented Products by Sublicensees within the Field in the Territory
                  in
                  each Royalty Year:

              

      

       

    

    
      	
              Amount
                of Net Sales on which royalties are paid to

            	
              Percentage
                of

            
	
              Rosetta
                Genomics by Sublicensees

            	
              Sublicensee

            
	
               

            	
              Royalty
                to

            
	
               

            	
              Be
                paid to U.S

            
	
               

            	
              Genomics

            
	 	 
	
              Up
                to and including US$[***] million

               

            	
              [***]%

               

            
	
              Above
                US$[***] million up to and including US$[***] million

               

            	
              [***]%

               

            
	
              Above
                US$[***] million up to and including US$[***] million

               

            	
              [***]%

               

            
	
              Above
                US$[***] million

               

            	
              [***]%

               

            

    

    
    

     

    
      	(v)     
               	
              In
                the event Rosetta Genomics or any of its Affiliates pays royalties
                on Net
                Sales in excess of [***] percent ([***]%) in the aggregate to US
                Genomics
                and one or more Third Parties to obtain rights that are determined
                to be
                necessary, based on the advice of patent counsel to Rosetta Genomics,
                with
                respect to the sale of any Product or Service in the Field, Rosetta
                Genomics shall have the right to reduce the amount of royalties owing
                to
                US Genomics under Section 5.1(i), (ii), (iii) or (iv) by [***] percent
                ([***]%) of the amount by which such aggregate royalties to US Genomics
                and such Third Party or Third Parties exceeds [***] percent ([***]%)
                of
                Net Sales; provided,
                however,
                that, the royalty paid to US Genomics shall not be reduced by operation
                of
                this Section 5.1(v) by more than [***] percent ([***]%) of what would
                otherwise be owed under Section 5.1(i), (ii), (iii) or (iv). For
                example,
                if Net Sales by Rosetta Genomics and its Affiliates under Section
                5.1(i)
                were $[***] million, and Rosetta Genomics paid a royalty equal to
                [***]
                percent ([***]%) of Net Sales to a Third Party, then the royalty
                paid by
                Rosetta Genomics to US Genomics on the first $[***] million of Net
                Sales
                would not be reduced; the royalty paid by Rosetta Genomics to US
                Genomics
                on the second $[***] million of Net Sales would be reduced by [***]
                of
                [***] percent ([***]%) and the royalty paid by Rosetta Genomics to
                US
                Genomics on the last $[***] million of Net Sales would be reduced
                by [***]
                percent ([***]%).

            

    

     

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	(vi)      	
              In
                the event that as a result of the sale by Rosetta Genomics of any
                Product
                or Service, US Genomics is required to pay royalties to any Third
                Party in
                consideration for the license of patent rights then Rosetta Genomics
                will
                reimburse US Genomics for [***] percent ([***]%) of such payment
                so long
                as such reimbursement, together with all royalties paid to US Genomics
                and
                Third Parties (including amounts reimbursed by Rosetta Genomics pursuant
                to this Section) by Rosetta Genomics or any of its Affiliates with
                respect
                to the sale of such Product or Service, does not exceed [***] percent
                ([***]%) of Net Sales in the aggregate. To the extent such reimbursement
                and royalties would exceed [***] percent ([***]%) of Net Sales in
                the
                aggregate, Rosetta Genomics shall instead reimburse US Genomics for
                [***]
                percent ([***]%) of such payment by US Genomics to the Third Parties.
                Notwithstanding the foregoing, in no event shall the amount payable
                by
                Rosetta Genomics under this Section 5.1(vi) with respect to the sale
                of
                any Product or Service exceed [***] percent ([***]%) of the Net Sales
                thereof.

            

    

     

    As
      a
      first example, if the Rosetta royalty obligation to US Genomics was [***]%
      and
      Rosetta was required to pay an [***]% royalty for necessary 3rd
      party
      rights, it would be entitled to deduct [***]% ([***]% of [***]%) from the amount
      owed to US Genomics. However, if US Genomics was also obligated to pay [***]%
      to
      another 3rd
      party,
      Rosetta would reimburse [***]% ([***]% of [***]%) of this to US Genomics. Under
      this combined scenario, US Genomics would net [***]% of sales ([***] - [***]
      -
      [***] +[***]). Rosetta’s total royalty obligation would be [***]% ([***] + [***]
      - [***] + [***]).

     

    As
      a
      second example, if the Rosetta royalty obligation to US Genomics was [***]%
      and
      Rosetta was required to pay a [***]% royalty for necessary 3rd
      party
      rights and US Genomics was obligated to pay [***]% to another 3rd
      party,
      US Genomics would net [***]% of sales ([***] - [***] +[***]) and Rosetta’s total
      royalty obligation would be [***]% ([***] + [***] + [***]).

     

    
      	(vii) 
                 	
              Royalties
                on Net Sales, at the rates set forth above, shall accrue as of the
                date of
                the applicable First Commercial Sale in any country and shall continue
                and
                accrue on Net Sales (a) in a country where a Valid Claim included
                within
                the US Genomics Patent Rights exists, until the later of the date
                of
                expiry of such patent in such country or the expiry of the period
                of
                twelve (12) years commencing with the date of the First Commercial
                Sale
                (b) in any other country, until the expiry of the period of twelve
                (12)
                years commencing with First Commercial Sale in such
                country.

            

    

     

    
      	(viii) 
               	
              Following
                the expiration of the last applicable period set forth in subsection
                (v)
                above, (a) Rosetta Genomics shall have the right under this Agreement
                to
                directly and indirectly (through sublicensees or otherwise) continue
                to
                manufacture, use, market, commercialize, distribute and sell and
                otherwise
                dispose of Products and Services, throughout the world, without having
                to
                pay royalties or any other consideration to US Genomics and (b) US
                Genomics shall not grant any exclusive license to the US Genomics
                Know How
                to any Third Party for the Field.

            

    

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	(ix)
                   	
              Rosetta
                Genomics shall have the right, at any time and in its sole discretion,
                to
                terminate its obligation to make any further payment to US Genomics
                under
                this Article 5 by paying to US Genomics the sum of [***] Dollars
                ($[***])
                less all amounts previously paid to US Genomics
                hereunder.

            

    

     

    
      	(x)     	
              In
                the event that (i) Rosetta Genomics does not commercialize either
                any US
                Genomics Based Product or any Other US Genomics Patented Product,
                and (ii)
                Rosetta Genomics commercializes a product or service for Early Detection
                of Lung Cancer based on microRNA markers in sputum and/or blood that
                is
                not a US Genomics Based Product or an Other US Genomics Patented
                Product,
                then Rosetta Genomics will pay US Genomics [***] percent ([***]%)
                of the
                direct cost to US Genomics of the US Genomics Platforms and reagent
                kits
                provided to Rosetta Genomics for use in the Development Program pursuant
                to Section 3.1(iii), such payment to be made on the first anniversary
                of
                the first commercial sale of the first such product or
                service.

            

    

     

    
      	5.2.  	
              Sublicense
                Income.
                Rosetta Genomics will pay US Genomics [***]% of all Sublicense Income
                received from Sublicensees in each Calendar
                Quarter.

            

    

     

    
      	5.3.  	
              Reports;
                    Payment of Royalty.
                Commencing with the first Calendar Quarter in which royalty or other
                payments are due, Rosetta Genomics shall furnish to US Genomics a
                quarterly written report for such Calendar Quarter (the “Quarterly
                Report”), each showing the sales of all Products and Services subject to
                royalty or other payments sold by Rosetta Genomics and its Affiliates
                and
                all Sublicense Income and royalties received from Sublicensees during
                the
                reporting period and the royalties or other payments payable under
                this
                Agreement. Quarterly Reports shall be due on the sixtieth (60th)
                day
                following the close of each Calendar Quarter. Royalties and other
                payments
                shown to have accrued by each Quarterly Report, if any, shall be
                due and
                payable on the date such Quarterly Report is due. Rosetta Genomics
                shall
                keep (and shall require its Affiliates to keep) complete and accurate
                records in sufficient detail to enable Net Sales and the royalties
                and
                other payments payable hereunder, to be determined, reconciled and
                verified.

            

    

     

    
      	5.4.  	
              Audits.

            

    

     

    
      	5.4.1  	
              Upon
                the written request of US Genomics and not more than once in each
                Calendar
                Year, Rosetta Genomics shall permit an independent certified public
                accounting firm of recognized standing in the United States or Israel,
                selected by US Genomics and reasonably acceptable to Rosetta Genomics,
                to
                have access during normal business hours at times mutually convenient
                to
                the Parties and upon reasonable notice to Rosetta Genomics to such
                of the
                records of Rosetta Genomics as may be reasonably necessary to verify
                the
                accuracy of the royalty and other payment reports hereunder for any
                Royalty Year, for a period of up to three (3) years from the completion
                of
                such Royalty Year. The accounting firm shall report to US Genomics
                only
                the results of the work performed as contemplated by this Section
                5.4.1
                and the details concerning any
                discrepancies.

            

    

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	5.4.2  	
              If
                such accounting firm concludes that additional royalties or other
                payments
                were owed during such Royalty Year , Rosetta Genomics shall pay the
                additional royalties or other payments (plus accrued interest at
                the LIBOR
                rate as in effect on the date that such payment was first due, plus
                [***]
                ([***]%) percent) within ten (10) Business Days of the date US Genomics
                delivers to Rosetta Genomics such accounting firm’s written report so
                concluding, provided however, that in the event that Rosetta Genomics
                shall not be in agreement with the conclusions of such report Rosetta
                Genomics shall provide US Genomics with a written notice to such
                effect
                within such ten (10) Business Day period and such matter shall be
                resolved
                pursuant to the provisions of Section 11.6. In the event such accounting
                firm concludes that Rosetta Genomics overpaid amounts during such
                period,
                US Genomics shall reimburse Rosetta Genomics the amount of such
                overpayment within ten (10) Business Days of receipt of such accounting
                firm’s written report, provided however, that, in the event that US
                Genomics shall not be in agreement with the conclusions of such report
                US
                Genomics shall provide Rosetta Genomics with a written notice to
                such
                effect within such ten (10) Business Day period and such matter shall
                be
                resolved pursuant to the provisions of Section 11.6. The fees charged
                by
                such accounting firm shall be paid by US Genomics unless the audit
                (or in
                the case of a disagreement, the dispute resolution under Section
                11.6)
                establishes an underpayment by Rosetta Genomics of [***] percent
                ([***]%)
                or more.

            

    

     

    
      	5.4.3  	
              Each
                Party reviewing information under this Section 5.4 shall treat all
                financial information subject to review under this Section 5.4 in
                accordance with the confidentiality provisions of this Agreement
                and shall
                request a confidentiality agreement to the same effect from any accounting
                firm reviewing information under this Section
                5.4.

            

    

     

    
      	5.5.  	
              Payments.
                All payments to be made under this Agreement shall be made in United
                States Dollars and shall be paid by bank wire transfer or by automated
                clearinghouse (electronic funds transfer) in immediately available
                funds
                to such bank account designated in writing by each Party to the other
                from
                time to time. Bank charges necessary for making the bank transfer
                shall be
                incurred by the Party making the
                transfer.

            

    

     

    
      	5.6.  	
              Payment
                Exchange Rate.
                In the case of sales outside the United States, the rate of exchange
                to be
                used in computing the amount of currency equivalent in United States
                dollars due any Party shall be calculated quarterly in accordance
                with
                GAAP and based on the conversion rates for buying United States dollars
                on
                the last Business Day of each Calendar Quarter published in the Wall
                Street Journal, Eastern edition.

            

    

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	5.7.  	
              Tax
                Withholding.
                The royalties, milestones and other amounts payable by Rosetta Genomics
                to
                US Genomics pursuant to this Agreement (“Payments”)
                shall not be reduced on account of any taxes and are net of all such
                taxes. US Genomics alone shall be responsible for paying any and
                all taxes
                (other than withholding taxes or deduction of tax at source required
                by
                applicable law to be paid by Rosetta Genomics) levied on it by account
                of
                its receipt of any Payments it receives under this
                Agreement.

            

    

     

    
      	5.8.  	
              Interest
                on Late Payments.
                Except as otherwise set forth in this Agreement, any payment by Rosetta
                Genomics that is not paid on or before the date such payment is due
                under
                this Agreement shall bear interest, to the extent permitted by applicable
                law, at a rate per annum equal to the LIBOR rate as in effect on
                the date
                that such payment was first due, plus [***] percent ([***]%) calculated
                on
                the number of days such payment is
                delinquent.

            

    

     

    
      	5.9.  	
              Blocked
                Currencies.
                If by law, regulations or fiscal policy of a particular country in
                the
                Territory, remittance of royalties in United States Dollars is restricted
                or forbidden, written notice thereof shall promptly be given to US
                Genomics, and payment of the royalty shall be made by the deposit
                thereof
                in local currency to the credit of US Genomics in a recognized banking
                institute reasonably designated by US Genomics by written notice
                to
                Rosetta Genomics. When in any country in the Territory the law or
                regulations prohibit both the transmittal and the deposit of royalties
                on
                sales in such country, royalty payments shall be suspended for as
                long as
                such prohibition is in effect and as soon as such prohibition ceases
                to be
                in effect, all royalties that Rosetta Genomics would have been under
                an
                obligation to transmit or deposit but for the prohibition shall forthwith
                be deposited or transmitted, to the extent
                allowable.

            

    

     

    ARTICLE
      VI

     

    REPRESENTATIONS
      AND WARRANTIES

     

    
      	6.1.  	
              US
                Genomics Representations and Warranties.
                US Genomics represents and warrants to Rosetta Genomics that, as
                of the
                date hereof

            

    

     

    
      	(i)          
                	
              US
                Genomics has the right to grant Rosetta Genomics the licenses granted
                to
                Rosetta Genomics in this Agreement;

            

    

     

    
      	(ii)          
               	
              this
                Agreement has been duly executed and delivered by US Genomics and
                constitutes its legal, valid, and binding obligation, enforceable
                against
                it in accordance with its terms;

            

    

     

    
      	(iii)        
                	
              no
                approval, authorization, consent, or other order or action of or
                filing
                with any court, administrative agency or other governmental authority
                is
                required for the execution and delivery by it of this Agreement or
                the
                consummation by it of the transactions contemplated
                hereby;

            

    

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	(iv)        
               	
              to
                its knowledge, it is the sole owner of all rights related to the
                US
                Genomics Know-How and US Genomics Patent Rights, free and clear of
                all
                liens, claims and pledges, security interest and restrictions to
                the
                extent that any of the foregoing would limit the rights granted
                hereunder;

            

    

     

    
      	(v)         
               	
              to
                its knowledge and except as otherwise disclosed in writing to Rosetta
                Genomics, the use of the US Genomics Platform in the Field in the
                Territory to the extent contemplated hereunder, will not infringe
                any
                patent right of any Third Party;

            

    

     

    
      	(vi)   
                    	
              except
                as otherwise disclosed in writing to Rosetta Genomics, it is under
                no
                liability or obligation to make any payments by way of royalties,
                fees or
                otherwise with respect to the use by Rosetta Genomics of US Genomics
                Know-How and/or US Genomics Patent Rights, Products and/or
                Services;

            

    

     

    
      	(vii)    
                  	
              to
                its knowledge, in the development of the US Genomics Know-How and/or
                the
                US Genomics Patent Rights, it did not wrongfully or illegally use
                any
                intellectual property rights of any entity or person, including any
                former
                or current employee;

            

    

     

    
      	(viii)  
                   	
              it
                has the full right, power and authority to enter into and deliver
                this
                Agreement, to perform and to grant the licenses granted under Article
                II
                hereof and to consummate the transactions contemplated hereby. All
                corporate acts and other proceedings required to be taken to authorize
                such execution, delivery, and consummation have been duly and properly
                taken and obtained; and

            

    

     

    
      	(ix)       
                	
              there
                are no actions, suits, proceedings, claims, judgments or settlements
                against or owed by US Genomics or pending or threatened actions,
                suits,
                proceedings, claims or litigation against US Genomics relating to
                the US
                Genomics Patent Rights or US Genomics
                Know-How.

            

    

     

    
      	6.2.  	
              US
                Genomics’ Warranty Disclaimer

            

    

     

    EXCEPT
      AS
      OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, US GENOMICS MAKES NO WARRANTY,
      EXPRESS OR IMPLIED, WITH RESPECT TO THE US GENOMICS PATENT RIGHTS, US GENOMICS
      KNOW-HOW OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND HEREBY DISCLAIMS
      WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND
      NON-INFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE FOREGOING.

     

    
      	6.3.  	
              Rosetta
                Genomics’ Representations and Warranties.
                Rosetta Genomics represents and warrants to US Genomics that as of
                the
                date hereof:

            

    

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	(i)         
                	
              Rosetta
                Genomics has the right to grant US Genomics the licenses granted
                to US
                Genomics in this Agreement;

            

    

     

    
      	(ii)        
                	
              this
                Agreement has been duly executed and delivered by Rosetta Genomics
                and
                constitutes its legal, valid, and binding obligations, enforceable
                against
                it in accordance with its terms;

            

    

     

    
      	(iii)        
               	
              it
                has full corporate power and authority to execute and deliver this
                Agreement and to consummate the transactions contemplated hereby.
                All
                corporate acts and other proceedings required to be taken to authorize
                such execution, delivery, and consummation have been duly and properly
                taken and obtained;

            

    

     

    
      	(iv)       
               	
              no
                approval, authorization, consent, or other order or action of or
                filing
                with any court, administrative agency or other governmental authority
                is
                required for the execution and delivery by it of this Agreement or
                the
                consummation by it of the transactions contemplated
                hereby;

            

    

     

    
      	(v)      
                	
              to
                its knowledge, the use of the Rosetta Genomics Patent Rights in the
                Field
                in the Territory to the extent contemplated hereunder, will not infringe
                any patent right of any Third Party;
                and

            

    

     

    
      	(vi)     
                	
              except
                as disclosed in writing it is under no liability or obligation to
                make any
                payments by way of royalties, fees or otherwise with respect to the
                use of
                the Rosetta Genomics Know-How and/or Rosetta Genomics Patent Rights
                in the
                development or commercialization of Products and/or
                Services.

            

    

     

    
      	6.4.  	
              Rosetta
                Genomics’ Warranty Disclaimer

            

    

     

    EXCEPT
      AS
      OTIIERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, ROSETTA GENOM1CS MAKES NO
      WARRANTY, EXPRESS OR IMPLIED, WITH RESPECT TO THE ROSETTA GENOMICS PATENT
      RIGHTS, ROSETTA GENOMICS KNOW-HOW OR OTHER SUBJECT MATTER OF THIS AGREEMENT.
      ROSETTA GENOMICS DOES NOT REPRESENT THAT IT CAN SUCCESSFULLY DEVELOP OR
      COMMERCIALIZE ANY PRODUCT OR SERVICE.

     

    ARTICLE
      VII

     

    PATENT
      MATTERS

     

    
      	7.1.  	
              Filing,
                Prosecution and Maintenance of Patent Applications or
                Patents

            

    

     

    
      	7.1.1    
                	
              Rosetta
                Genomics Patent Rights.
                Rosetta Genomics, acting through patent counsel of its choice, shall
                be
                responsible, at its sole expense, for the preparation, filing, prosecution
                and maintenance of all Rosetta Genomics Patent Rights and patents
                covering
                Rosetta Genomics Improvements. At Rosetta Genomics’ request, US Genomics
                shall cooperate with Rosetta Genomics in all reasonable respects,
                at
                Rosetta Genomics’ expense, in connection with such preparation, filing,
                prosecution and maintenance of Rosetta Genomics Patent Rights and
                Rosetta
                Genomics Improvements.

            

    

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	7.1.2     
               	
              US
                Genomics Patent Rights.
                US Genomics, acting through patent counsel of its choice, shall be
                responsible, at its own expense, for the preparation, filing, prosecution
                and maintenance of all US Genomics Patent Rights and patents covering
                US
                Genomics Improvements. At US Genomics’ request, Rosetta Genomics shall
                cooperate with and assist US Genomics in all reasonable respects,
                at US
                Genomics’ expense, in connection with such preparation, filing,
                prosecution and maintenance of US Genomics Patent Rights and US Genomics
                Improvements.

            

    

     

    
      	7.1.3    
                	
              Joint
                Program Patent Rights.
                The Parties will cooperate to jointly select outside patent counsel
                to
                handle the filing, prosecution and maintenance of patents and patent
                applications claiming Joint Information and Inventions. The Parties
                shall
                jointly determine which Party shall control the prosecution of patent
                applications claiming inventions that are Joint Information and
                Inventions. The fees of counsel and the other costs and expenses
                related
                to patents and patent applications claiming Joint Information and
                Inventions shall be shared equally by the Parties. Should one Party
                desire
                not to share in the cost of any such patent or patent applications,
                the
                other Party shall gain sole control of the filing, prosecution and
                maintenance of such patents or patent applications, which shall be
                deemed
                to be the Information and Inventions of such Party and such Party
                shall
                have sole responsibility for filing, prosecution and maintenance
                expenses
                with respect thereto.

            

    

     

    
      	7.1.4     
               	
              Right
                of Other Party to Prosecute and Maintain Patents.
                Any Party having the first right to file, prosecute and maintain
                the
                patent applications and patents referred to in this Section 7.1 shall
                give
                notice to the other Party of any desire to cease prosecution and/or
                maintenance of such patent rights and, in such case, shall permit
                the
                other Party, at its sole discretion, to continue prosecution and/or
                maintenance at its own expense in the name of the first
                Party.

            

    

     

    
      	7.2.  	
              Patent
                Office Proceedings.
                Each Party shall reasonably cooperate with the other Party with respect
                to
                any patent office proceeding.

            

    

     

    
      	7.3.  	
              Enforcement
                and Defense.

            

    

     

    
      	7.3.1    
                	
              Each
                Party shall promptly give the other Party notice of any infringement
                in
                the Territory of any patent application or patent included in the
                US
                Genomics Patent Rights or Rosetta Genomics Patent Rights that comes
                to
                such Party’s attention. The Parties will thereafter consult and cooperate
                fully to determine a course of action with respect to jointly owned
                patent
                rights, including, without limitation, the commencement of legal
                action by
                either Party. Each Party solely owning patent rights hereunder shall
                have
                the sole right to initiate and prosecute such legal action against
                any
                such infringer at its own expense in its own name or to control the
                defense of any declaratory judgment action relating to such patent
                rights.

            

    

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	7.3.2     
               	
              For
                any such legal action or defense, in the event that any Party is
                unable to
                initiate, prosecute, or defend such action solely in its own name,
                the
                other Party shall join such action voluntarily and shall execute
                all
                documents reasonably necessary for the Party to prosecute, defend
                and
                maintain such action. In connection with any such action, the Parties
                will
                cooperate and will provide each other with any information or assistance
                that either reasonably may request. Each Party shall keep the other
                informed of developments in any such action or proceeding, including,
                to
                the extent permissible by law, the status of any settlement negotiations
                and the terms of any offer related
                thereto.

            

    

     

    
      	7.3.3     
               	
              Any
                recovery obtained by Rosetta Genomics or US Genomics in any such
                action or
                proceeding shall be shared as follows in the following order of
                priority:

            

    

     

    
      	(i)         
                	
              the
                Party that initiated and prosecuted or maintained the defense of,
                the
                action, shall recoup all of its costs and expenses incurred in connection
                with the action, whether by settlement or
                otherwise;

            

    

     

    
      	(ii)        
                	
              the
                other Party shall next recoup all of its costs and expenses incurred
                in
                connection with the action, whether by settlement or
                otherwise;

            

    

     

    
      	(iii)        
               	
              if
                US Genomics initiated and prosecuted, or maintained the defense of,
                the
                action, the amount of any recovery remaining then shall be retained
                by US
                Genomics; and

            

    

     

    
      	(iv)         	
              if
                Rosetta Genomics initiated and prosecuted, or maintained the defense
                of,
                the action, the amount of any recovery remaining shall be retained
                by
                Rosetta Genomics, except that US Genomics shall receive a portion
                equivalent to the royalties they would have received on such remaining
                amount if such amount were deemed Net
                Sales.

            

    

     

    
      	7.4.  	
              Patent
                Term Extensions and Supplemental Protection Certificates.
                The Parties shall cooperate in obtaining patent term extensions or
                supplemental protection certificates or their equivalents in any
                country
                in the Territory where applicable and where desired by Rosetta Genomics.
                If elections with respect to obtaining such extension or supplemental
                protection certificates are to be made, Rosetta Genomics shall have
                the
                first right to make the election, in consultation with US
                Genomics.

            

    

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    ARTICLE
      VIII

     

    TERM
      AND TERMINATION

     

    
      	8.1.  	
              Term
                and Expiration.
                This Agreement shall be effective as of the Effective Date and, unless
                terminated earlier pursuant to Section 8.2 or Section 8.3 below,
                shall
                continue in effect with respect to all US Genomics Patent Rights,
                US
                Genomics Know-How and any other rights licensed to Rosetta Genomics
                hereunder, until the expiration of all payment obligations under
                Section
                5.1 hereof.

            

    

     

    
      	8.2.  	
              Termination
                by Notice.
                Notwithstanding anything contained herein to the contrary, Rosetta
                Genomics shall have the right, in its reasonable business or scientific
                judgment, to terminate this Agreement in its entirety at any time
                by
                giving ninety (90) days advance written notice to US Genomics. Except
                as
                expressly set forth in this Agreement (including, without limitation,
                those rights and obligations respecting confidentiality and indemnity
                hereunder), the rights and obligations hereunder of the Parties,
                excluding
                any payment obligation which has accrued prior to the termination
                date or
                that is required by Section 5.1(i), (ii), (iii) or (iv), shall terminate
                (including Rosetta Genomics’ rights and obligations with respect to the US
                Genomics Patent Rights and the US Genomics Know-How); in any event
                of
                termination by Rosetta Genomics according to this Section 8.2, US
                Genomics
                shall not be entitled to any compensation or any other payment whatsoever
                except as set forth in Section 5.1(i), (ii), (iii) or (iv) and excluding
                any obligation which has accrued prior to the termination date, which
                shall be promptly paid by Rosetta
                Genomics.

            

    

     

    
      	8.3.  	
              Termination
                for Cause.
                Either Party may terminate this Agreement by notice to the other
                Party at
                any time during the term of this Agreement as
                follows:

            

    

     

    
      	(i)          
               	
              if
                the other Party is in breach of its material obligations hereunder
                (other
                than a breach for failure to make payments covered in Section 8.3(ii))
                below), which breach is not cured within ninety (90) days after the
                date
                of the notice from the non-defaulting Party specifying the breach
                in
                reasonable detail, provided, however, that if a curable breach is
                not
                capable of being cured within ninety (90) days of such written notice,
                the
                Agreement may not be terminated so long as the breaching Party commences
                and is taking commercially reasonable actions to cure such breach
                as
                promptly as practicable. In any event, if a curable breach has not
                been
                cured within one-hundred eighty (180) days after notice requesting
                cure,
                then the non-breaching Party may terminate this Agreement effective
                upon
                expiration of such one-hundred eighty (180) day
                period;

            

    

     

    
      	(ii)         
               	
              if
                the defaulting Party fails to pay the other Party any amounts due
                and
                payable to such Party (together with any accrued interest at the
                rate set
                forth in this Agreement) and has not cured such breach within thirty
                (30)
                days after notice requesting cure of the breach, the Party entitled
                to
                receive payment shall have the right to (i) terminate this Agreement
                immediately upon expiration of such thirty (30) day period and institute
                an action to collect such overdue amounts and to pursue any other
                rights
                or remedies such Party may have at law or in equity or (ii) institute
                an
                action to collect such amounts without terminating this Agreement;
                or

            

    

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	(iii)       
                	
              upon
                the filing or institution of bankruptcy, reorganization, liquidation
                or
                receivership proceedings, or upon an assignment of all or substantially
                all of the assets for the benefit of creditors by the other Party;
                provided,
                however,
                in the case of any involuntary bankruptcy, reorganization, liquidation,
                receivership or assignment proceeding such right to terminate shall
                only
                become effective if the Party consents to the involuntary proceeding
                or
                such proceeding is not dismissed within ninety (90) days after the
                filing
                thereof.

            

    

     

    
      	8.4.  	
              Effect
                of Expiration or Termination.

            

    

     

    
      	8.4.1     
                	
              Expiration
                or termination of this Agreement shall not relieve the Parties of
                any
                obligation accruing prior to such expiration or termination. In addition
                to any other provisions of this Agreement which by their terms continue
                after the expiration of this Agreement, the provisions of Article
                IV and
                Article X shall survive the expiration or termination of this Agreement.
                In addition, any other provision required to interpret and enforce
                the
                Parties’ rights and obligations under this Agreement shall also survive,
                but only to the extent required for the full observation and performance
                of this Agreement. Any expiration or early termination of this Agreement
                shall be without prejudice to the rights of any Party against the
                other
                Party accrued or accruing under this Agreement prior to termination,
                including the obligation to pay royalties for Product(s) sold prior
                to
                such termination. Except as expressly set forth herein, the rights
                to
                terminate as set forth herein shall be in addition to all other rights
                and
                remedies available under this Agreement, at law, in equity, or
                otherwise.

            

    

     

    
      	8.4.2      
               	
              Except
                as otherwise provided in this Section 8, in the event (a) of termination
                of this Agreement by Rosetta Genomics in accordance with Section
                8.2 or
                (b) of termination of this Agreement by US Genomics in accordance
                with
                Section 8.3(i) or Section 8.3(ii), Rosetta Genomics shall have no
                further
                rights with respect to the US Genomics Patent Rights and the US Genomics
                Know-How, and Rosetta Genomics shall promptly return any and all
                US
                Genomics Patent Rights and all US Genomics Know-How in its possession
                at
                the time of termination.

            

    

     

    
      	8.4.3      
               	
              Rights
                in Bankruptcy.
                All rights and licenses granted under or pursuant to this Agreement
                by US
                Genomics are, and shall otherwise be deemed to be, for purposes of
                Section
                365(n) of the United States Bankruptcy Code, licenses of rights to
                “intellectual property” as defined under Section 101 of the United States
                Bankruptcy Code. The Parties agree that Rosetta Genomics, as licensee
                of
                such rights under this Agreement, shall retain and may fully exercise
                all
                of its rights and elections under the United States Bankruptcy Code.
                The
                Parties further agree that, in the event of the commencement of a
                bankruptcy proceeding by or against US Genomics under the United
                States
                Bankruptcy Code, Rosetta Genomics shall be entitled to a complete
                duplicate of (or complete access to, as appropriate) any such intellectual
                property and all embodiments of such intellectual property, which,
                if not
                already in Rosetta Genomics’ possession, shall be promptly delivered to it
                (i) upon any such commencement of a bankruptcy proceeding upon Rosetta
                Genomics’ written request therefor, unless US Genomics continues to
                perform all of its obligations under this Agreement or (ii) if not
                delivered under clause (i) above, following the rejection of this
                Agreement by or on behalf of US Genomics upon written request therefor
                by
                Rosetta Genomics.

            

    

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    ARTICLE
      IX

     

    MANUFACTURING
      AND SUPPLY

     

    Following
      the completion of Phase II of the Development Plan, US Genomics and Rosetta
      Genomics shall negotiate a Supply Agreement providing for US Genomics to supply
      US Genomics Platforms and either finished US Genomics Based Products or reagents
      for US Genomics Based Products to Rosetta Genomics at a price equal to the
      fully
      loaded manufacturing cost thereof plus [***]% and for maintenance and service
      of
      US Genomics Platforms by US Genomics.

     

    ARTICLE
      X

     

    INDEMNITY

     

    
      	10.1.  	
              General.
                For purposes of this Article 10 “Indemnified Parties” refers to US
                Genomics, its Affiliates and the officers, directors, employees and
                agents
                of US Genomics and its Affiliates when Rosetta Genomics is the indemnitor,
                and “Indemnified Parties” refers to Rosetta Genomics, its Affiliates and
                officers, directors, employees and agents of Rosetta Genomics and
                its
                Affiliates when US Genomics is the
                indemnitor.

            

    

     

    
      	10.1.1    
                	
              Rosetta
                Genomics Indemnity.
                Rosetta Genomics shall indemnify and hold harmless the US Genomics
                Indemnified Parties and each of them from any and all losses, damages,
                liabilities and costs (including reasonable attorneys’ fees and expenses)
                (collectively, “Losses”) associated with any claim, complaint, suit,
                proceeding or cause of action (collectively, “Claims”) against any US
                Genomics Indemnified Party by a third party (i) alleging physical
                or other
                injury, including death, arising out of, based upon, or resulting
                from the
                research, development, testing, registration, storage, handling,
                packaging, distribution, marketing, sale or use of any Product or
                Service
                by Rosetta Genomics, its Affiliates, Sublicensees or distributors,
                or (ii)
                arising out of any breach by Rosetta Genomics of any representation,
                warranty or covenant hereunder, except in either case to the extent
                such
                Losses are determined to have resulted from the negligence or willful
                misconduct of any US Genomics Indemnified
                Party.

            

    

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	10.1.2     
               	
              US
                Genomics Indemnity.
                US Genomics shall indemnify and hold harmless the Rosetta Genomics
                Indemnified Parties and each of them from any and all Losses, associated
                with any Claim against any Rosetta Genomics Indemnified Party by
                a third
                party (i) alleging physical or other injury, including death arising
                out
                of, based upon, or resulting from the research, development, testing,
                registration, manufacture, storage, handling, packaging, distribution,
                marketing, sale or use of any Product or Service by US Genomics,
                its
                Affiliates, sublicensees or distributors (excluding Rosetta Genomics),
                or
                (ii) arising out of any breach by US Genomics of any representation,
                warranty or covenant hereunder, except in either case to the extent
                such
                Losses are determined to have resulted from the negligence or willful
                misconduct of any Rosetta Genomics Indemnified
                Party.

            

    

     

    
      	10.2.  	
              Conditions
                to Indemnification.
                An Indemnified Party seeking recovery under this Article 10 in respect
                of
                a Claim shall give prompt notice of such Claim to the Party from
                which
                recovery is sought (the “Indemnifying Party”) and, provided that the
                Indemnifying Party is not contesting its obligation under this Article
                10,
                shall permit the Indemnifying Party to control any litigation relating
                to
                such Claim and the disposition of such Claim; provided that the
                Indemnifying Party shall (a) act reasonably and in good faith with
                respect
                to all matters relating to the settlement or disposition of such
                Claim as
                the settlement or disposition relates to Parties being indemnified
                under
                this Article 10, (b) not settle or otherwise resolve such Claim without
                the prior written consent of the Indemnified Party (which consent
                shall
                not be unreasonably withheld, conditioned or delayed). The Indemnified
                Party shall cooperate with the Indemnifying Party in its defense
                of any
                such Claim in all reasonable respects and shall have the right to
                be
                present in person or through counsel at all legal proceedings with
                respect
                to such Claim.

            

    

     

    
      	10.3.  	
              Survival.
                Each Party acknowledges and hereby agrees that the obligations set
                forth
                in this Article X shall survive the termination or expiration of
                this
                Agreement until the later of (a) [***] ([***]) years from the date
                of
                expiration or termination, or (b) the expiration of all applicable
                statutes of limitations.

            

    

     

    
      	10.4.  	
              Insurance.
                Both Rosetta Genomics and US Genomics shall maintain, at their respective
                expense, sufficient product liability insurance and other insurance
                insuring against all liability, including product liability, personal
                injury, physical injury and property damage in such amounts as are
                reasonable and customary for companies of comparable size and activities
                in the U.S. diagnostics industry and in relation to their respective
                liability/risk exposures under this
                Agreement.

            

    

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    ARTICLE
      XI

     

    MISCELLANEOUS

     

    
      	11.1.  	
              Force
                Majeure.
                Neither Party shall be held liable or responsible to the other Party
                nor
                be deemed to have defaulted under or breached this Agreement for
                failure
                or delay in fulfilling or performing any term of this Agreement during
                the
                period of time when such failure or delay is caused by or results
                from
                causes beyond the reasonable control of the affected Party including,
                but
                not limited to, fire, flood, embargo, war, acts of war (whether war
                be
                declared or not), insurrection, riot, civil commotion, strike, lockout
                or
                other labor disturbance, act of God or act, omission or delay in
                acting by
                any governmental authority or the other Party. The affected Party
                shall
                notify the other Party of such force majeure circumstances as soon
                as
                reasonably practicable and the affected Party shall use all reasonable
                efforts to avoid or remove such causes of non-performance as promptly
                as
                practicable and shall promptly continue performance whenever such
                causes
                are removed. When such circumstances arise, the Parties shall discuss
                what, if any, modification of the terms of this Agreement may be
                required
                in order to arrive at an equitable
                solution.

            

    

     

    
      	11.2.  	
              Assignment.
                This Agreement may not be assigned or otherwise transferred, nor,
                except
                as expressly provided hereunder, may any right or obligations hereunder
                be
                assigned or transferred by a Party without the prior written consent
                of
                the other Party; provided,
                however,
                that either Party may assign this Agreement and its rights and obligations
                hereunder without the consent of the other Party hereto to an Affiliate
                or
                in connection with the transfer or sale of all or substantially all
                of its
                assets related to the Products or Services or its business or in
                the event
                of its merger or consolidation or change in control or similar
                transaction. Except as otherwise set forth herein, any permitted
                assignee
                shall assume all obligations of its assignor under this Agreement
                (without
                releasing the assignor of its obligations hereunder). Any assignment
                or
                attempted assignment contrary to the provisions hereof shall be null
                and
                void.

            

    

     

    
      	11.3.  	
              Severability.
                In the event that any of the provisions contained in this Agreement
                are
                held invalid, illegal or unenforceable in any respect, the validity,
                legality and enforceability of the remaining provisions contained
                herein
                shall not in any way be affected or impaired thereby, unless the
                absence
                of the invalidated provision(s) adversely affect the substantive
                rights of
                the Parties. In such event, the Parties shall replace the invalid,
                illegal
                or unenforceable provision(s) with valid, legal and enforceable
                provision(s) which, insofar as practicable, implement the purposes
                of this
                Agreement.

            

    

     

    
      	11.4.  	
              Notices.
                All notices or other communications which are required or permitted
                hereunder shall be in writing and sufficient if delivered personally,
                sent
                by facsimile (and promptly confirmed by personal delivery, registered
                or
                certified mail or overnight courier), sent by a nationally-recognized
                overnight courier providing evidence of delivery or sent by registered
                or
                certified mail, postage prepaid, return receipt requested, addressed
                as
                follows:

            

    

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    If
      to
      Rosetta Genomics to:

     

    Rosetta
      Genomics, Ltd.

    10
      Plaut
      Street

    Science
      Park

    Rehovot,
      Israel

    Tel:
      972-8-948-4755

    Fax:
      972-8-948-4766

    Attention:
      Chief Executive Officer

     

    With
      a
      copy to the legal department and to:

     

    Rosetta
      Genomics, Inc.

    675
      US
      Highway 1, suite B119

    North
      Brunswick, NJ 08902

    Attention:
      Chief Executive Officer

     

    If
      to US
      Genomics to:

     

    US
      Genomics, Inc

    12
      Gill
      Street, suite 4700

    Woburn,
      MA 01801

    Tel:
      781
      939 6479

    Fax:
      781
      938 0060

    Attention:
      Chief Executive Officer

     

    or
      to
      such other address as the Party to whom notice is to be given may have furnished
      to the other Party in writing in accordance herewith. Any such communication
      shall be deemed to have been given when delivered if personally delivered or
      sent by facsimile on a Business Day, upon confirmed delivery by nationally
      recognized overnight courier if so delivered and on the third Business Day
      following the date of mailing if sent by registered or certified
      mail.

     

    
      	11.5.  	
              Applicable
                Law.
                The Agreement shall be governed by and construed in accordance with
                the
                laws of the State of New York (USA) without reference to any rules
                of
                conflict of laws.

            

    

     

    
      	11.6.  	
              Dispute
                Resolution.
                In the event of any dispute arising between the Parties in connection
                with
                this Agreement, the construction thereof, or the rights, duties or
                liabilities of either Party (each a “Disputed Matter”), the Disputed
                Matter shall be submitted to the Chief Executive Officers of the
                Parties
                for good faith resolution. In the event the Disputed Matter cannot
                be
                resolved by the good faith efforts of the Chief Executive Officers
                on or
                before thirty (30) days from the date such Disputed Matter is first
                presented for resolution, then such Disputed Matter shall be resolved
                by
                binding arbitration in accordance with the following
                procedures:

            

    

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	(a)          
               	
              The
                arbitration shall be conducted by a panel of three (3) persons experienced
                in the diagnostics industry who are independent of both Parties.
                Within
                thirty (30) days after initiation of arbitration, each Party shall
                select
                one person to act as arbitrator and the two Party-selected arbitrators
                shall select a third arbitrator within thirty (30) days of their
                appointment. If the arbitrators selected by the Parties are unable
                or fail
                to agree upon the third arbitrator, the third arbitrator shall be
                appointed by the American Arbitration Association (“AAA”). The place of
                arbitration shall be New York, New York, and all proceedings and
                communications shall be in English. Except as provided for differently
                herein, the arbitration shall be conducted under the rules of the
                AAA
                applicable to complex business
                disputes.

            

    

     

    
      	(b)         
                	
              Either
                Party may apply to the arbitrators for interim injunctive relief
                until the
                arbitration decision is rendered or the Disputed Matter is otherwise
                resolved. Either Party also may, without waiving any right or remedy
                under
                this Agreement, seek from any court having jurisdiction any injunctive
                or
                provisional relief necessary to protect the rights or property of
                that
                Party pending resolution of the Disputed Matter pursuant to this
                Section
                11.6. The arbitrators shall have no authority to award punitive or
                any
                other type of damages not measured by a Party’s compensatory damages. Each
                Party shall bear its own costs and expenses and attorneys’ fees, and the
                Party that does not prevail in the arbitration proceeding shall pay
                the
                arbitrators’ fees and any administrative fees of
                arbitration.

            

    

     

    
      	(c)         
                	
              Except
                to the extent necessary to confirm an award or decision or as may
                be
                required by applicable laws, neither a Party nor an arbitrator may
                disclose the existence, content, or results of an arbitration without
                the
                prior written consent of both Parties. In no event shall an arbitration
                be
                initiated after the date when commencement of a legal or equitable
                proceeding based on the Disputed Matter would be barred by the applicable
                New York statute of limitations.

            

    

     

    
      	(d)          
               	
              The
                Parties agree that, in the event of a Disputed Matter involving the
                alleged breach of this Agreement, neither Party may terminate this
                Agreement until resolution of the Disputed Matter pursuant to this
                Section
                11.6.

            

    

     

    
      	(e)          
               	
              The
                Parties hereby agree that any disputed performance or suspended
                performance pending the resolution of a Disputed Matter that the
                arbitrators determine to be required to be performed by a Party must
                be
                completed within a reasonable time period following the final decision
                of
                the arbitrators.

            

    

     

    
      	(f)          
               	
              The
                Parties hereby agree that any monetary payment to be made by a Party
                pursuant to a decision of the arbitrators shall be made in United
                Stales
                Dollars, free of any tax or other deduction. The Parties further
                agree
                that the decision of the arbitrators shall be the sole, exclusive
                and
                binding remedy between them regarding determination of Disputed Matters
                presented.

            

    

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	11.7.  	
              Entire
                Agreement.
                This Agreement, including all exhibits hereto, contains the entire
                understanding of the Parties with respect to the subject matter hereof.
                All express or implied agreements and understandings, either oral
                or
                written, heretofore made are expressly superseded by this Agreement.
                This
                Agreement may be amended, or any term hereof modified, only by a
                written
                instrument duly executed by all Parties
                hereto.

            

    

     

    
      	11.8.  	
              Independent
                Contractors.
                It is expressly agreed that the Parties shall be independent contractors
                and that the relationship between the Parties shall not constitute
                a
                partnership, joint venture or agency. Neither Party shall have the
                authority to make any statements, representations or commitments
                of any
                kind, or to take any action which shall be binding on the other Party,
                without the prior consent of such other Party. This Agreement shall
                not
                impose any obligation on either Party except as expressly set forth
                herein.

            

    

     

    
      	11.9.  	
              Amendment;
                Waiver.
                This Agreement may be amended, modified, superseded or canceled,
                and any
                of the terms of this Agreement may be waived, only by a written instrument
                executed by each Party or, in the case of waiver, by the Party or
                Parties
                waiving compliance. The delay or failure of any Party at any time
                or times
                to require performance of any provision shall in no manner affect
                the
                rights at a later time to enforce the same. The waiver by a Party
                hereto
                of any right hereunder or the failure to perform or of a breach by
                another
                Party shall not be deemed a waiver of any other right hereunder or
                of any
                other breach or failure by said other Party whether of a similar
                nature or
                otherwise.

            

    

     

    
      	11.10.  	
              Headings.
                The captions to the several Articles and Sections hereof are not
                a part of
                the Agreement, but are merely guides or labels to assist in locating
                and
                reading the several Articles and Sections
                hereof.

            

    

     

    
      	11.11.  	
              Counterparts.
                The Agreement may be executed in two or more counterparts, each of
                which
                shall be deemed an original, but all of which together shall constitute
                one and the same instrument.

            

    

     

    
      	11.12.  	
              Binding
                Effect.
                This Agreement shall be binding upon and inure to the benefit of
                the
                Parties and their respective legal representatives, successors and
                permitted assigns.

            

    

     

    
      	11.13.  	
              No
                Third Party Beneficiaries.
                Except as set forth in Article 10, no Third Party (including, without
                limitation, employees of either Party) shall have or acquire any
                rights by
                reason on this Agreement.

            

    

     

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	11.14.  	
              Further
                Assurances.
                Each of the Parties agrees to duly execute and deliver, or cause
                to be
                duly executed and delivered, such further instruments and do and
                cause to
                be done such further acts and things, including, without limitation,
                the
                filing of such additional assignments, agreements, documents and
                instruments, as the other Party may at any time and from time to
                time
                reasonably request in connection with this Agreement or to carry
                out more
                effectively the provisions and purposes of, or to better assure and
                confirm unto such other Party its rights and remedies under, this
                Agreement.

            

    

     

     

    THE
      REST OF THIS PAGE WAS INTENTIONALLY LEFT BLANK

    

    

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    IN
      WITNESS WHEREOF, the Parties have executed this Agreement as of the date first
      set forth above.

     

    ROSETTA
      GENOMICS, LTD.

    

    

    By:__________________________________

          
      Name:

          
      Title: President

    

    

    

    US
      GENOMICS, INC.

    

    

    By:__________________________________

          
Name:

          
      Title:
      Chief Executive Officer

    

    

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    EXHIBIT
      A

    

    

    US
      Genomics-Rosetta Genomics: Development Plan for Lung Cancer Early
      Diagnostics

     

    
      	
              Goal:

            	
              Develop
                a [***] for early detection of lung cancer,
                [***]

            

    

     

    Discovery
      stage:
      [***]
      and [***] of [***]

     

    Phase
      Ia:
      [***]
      based on [***] (Rosetta)

     

    
      	
              1.

            	
              [***]
                and [***]. At this stage the purpose is to[***] lung[***], so [***]
                should
                be [***] at [***] to get [***]

            

    

     

    
      	
              2.

            	
              [***]
                from [***]

            

    

     

    
      	
              3.

            	
              [***]

            

    

     

    
      	
              4.

            	
              [***]
                data to [***] a subset of [***] lung[***]These must be [***] lung
                [***]
                lung [***], based on at [***] will be given to[***] which are [***]
                lung
                [***] and are not [***] of [***] Rosetta will update USG as [***]
                lung[***], this phase may be [***]

            

    

     

    Phase
      Ib
      [***]
      from [***] (Rosetta)

     

    
      	
              1.

            	
              [***]
                for [***]

            

    

     

    
      	
              2.

            	
              [***]
                for [***]

            

    

     

    Phase
      Ic
      [***]
      USG [***] to enable [***] of the [***] (USG)

     

    
      	
              1.

            	
              [***]
                for USG [***]

            

    

     

    
      	
              2.

            	
              [***]
                of the [***] for these [***]

            

    

     

    
      	
              3.

            	
              [***]of
                suggested [***] lung [***] using USG
                [***]

            

    

     

    The
      [***]
      that will be [***] will be [***] after considering [***]

     

    Phase
      Id:
      [***]
      from USG to Rosetta including [***] for [***]

     

    Phase
      II:
      [***]
      lung[***]

     

    
      	
              1.

            	
              [***]
                lung [***]. At this stage the purpose is to [***]should be [***]
                to
                approach the [***] should be [***] will be later
                [***]

            

    

     

    
      	
              2.

            	
              [***]
                from [***]

            

    

     

    
      	
              3.

            	
              [***]
                using the USG [***] (USG [***] and the
                [***]

            

    

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	
              4.

            	
              [***]
                is expected to be[***]

            

    

     

    Validation
      Stage:
      [***]

     

    Phase
      IIIa
      [***]

     

    
      	
              Goal:

            	
              [***]
                of the [***] in the [***]

            

    

     

    
      	
              1.

            	
              [***]
                from at [***] of the [***] in the
                [***]

            

    

     

    
      	
              2.

            	
              [***]
                from [***]

            

    

     

    
      	
              3.

            	
              [***]
                on the USG [***]

            

    

     

    
      	
              4.

            	
              [***]
                at the [***]

            

    

     

    Phase
      IIIb

     

    
      	
              Goal:

            	
              [***]The
                details of the [***] will be [***]but it is [***] that this will[***]
                of
                the USG [***] and the [***]

            

    

     

    

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    EXHIBIT
      B

    US
      Genomics Patent Rights

    

    

    
      	
              USG
                REF. NO.

            	
              SERIAL
                NO.

            	
              FILING
                

              DATE

            	
              INVENTORS

            	
              TITLE

            	
              STATUS

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              
                [***]

              

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            

    

    
      	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	 	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	 	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	 	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	 	 	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            

    

     

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      

      
        	
                USG
                  REF. NO.

              	
                SERIAL
                  NO.

              	
                FILING

                DATE

              	
                INVENTORS

              	
                TITLE

              	
                STATUS

              
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              
	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              
	
                [***]

              	
                [***]

              	
                [***]

              

      

    

    
      	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	 	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            

    

    

    

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    EXHIBIT
      C

    

    Rosetta
      Genomics Patent Rights

    

    

    
      	
              RG
                ID

            	
              Country

            	
              App
                No

            	
              Filed

            	
              Inventors

            	
              Title

            	
              Earliest
                Priority App

            	
              Earliest
                Priority Date

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	 	 
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	 	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	 	 
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            

    

     

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.The
      Rockefeller University

     

    License
      Agreement

     

    This
      Agreement (this “Agreement”)
      is
      between The Rockefeller University, a New York nonprofit corporation
      (“Rockefeller”), and Rosetta Genomics Ltd., an Israeli corporation
      (“Company”).
      This
      Agreement will become effective on May 4, 2006 (the “Effective
      Date”).

     

    BACKGROUND

     

    Rockefeller
      owns certain intellectual property developed by Dr. Thomas Tuschl and his
      colleagues relating to micro RNA sequences. Rockefeller also owns certain
      applications for United States letters patent relating to the intellectual
      property. Company desires to obtain a co-exclusive license under the patent
      rights to exploit the intellectual property. Rockefeller has determined that
      the
      exploitation of the intellectual property by Company is in the best interest
      of
      Rockefeller and is consistent with its educational and research missions and
      goal.

     

    In
      consideration of the mutual obligations contained in this Agreement, and
      intending to be legally bound, the parties agree as follows:

     

    1.  LICENSE

     

    1.1  License
      Grant.
      Rockefeller grants to Company and its Affiliates a co-exclusive, as set forth
      in
      Section 1.3, world-wide license (the “License”)
      to
      make, have made, use, have used, import, sell, have sold and offer for sale
      and
      have offered for sale Licensed Products in the Field of Use during the Term
      (as
      such terms may be defined in Sections 1.2 and 6.1). Licensee has no right to
      sublicense except as set forth in Section 1.5. Rockefeller grants no other
      rights or licenses. 

     

    1.2  Related
      Definitions.
      The
      term “Affiliate”
      means
      a
      legal entity that is controlling, controlled by or under common control with
      Company and that has executed either this Agreement or a written Joinder
      Agreement agreeing to be bound by all of the terms and conditions of this
      Agreement. For purposes of this Section 1.2, the word “control”
means
      (x) the direct or indirect ownership of more than fifty percent (50%) of the
      outstanding voting securities of a legal entity, (y) the right to receive fifty
      percent (50%) or more of the profits or earnings of a legal entity, or (z)
      the
      right to determine the policy decisions of a legal entity. 

     

    The
      term
“Licensee”
means
      Company and its Affiliates.

     

    The
      term
“Licensed
      Products”
means
      products that are made, made for, used, imported, sold or offered for sale
      by
      Licensee and its sublicensees and that either (i) in the absence of this
      Agreement, would infringe at least one Valid Claim of the Rockefeller Patent
      Rights, (ii) use a process or machine covered by a Valid Claim of Rockefeller
      Patent Rights, or (iii) use, at least in part, any Rockefeller Technical
      Information covered by a Valid Claim of Rockefeller Patent Rights.

     

    The
      term
“Rockefeller
      Patent Rights”
means
      all patent rights represented by or issuing from: (a) the United States patent
      applications listed in Exhibit A; (b) any continuation, divisional and re-issue
      applications of (a); and (c) any foreign counterparts and extensions of (a)
      or
      (b). 

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    The
      term
“Rockefeller
      Technical Information”
means
      all the information contained in the patents and the patent applications listed
      in Exhibit A and any other technical information disclosed or referenced in
      Exhibit A.

     

    The
      term
“Field
      Of Use”
means
      Diagnosis of any disease or condition in humans.
      Specifically excluded from the Field of Use is any use for therapeutic purposes,
      whether said use is in vivo or in vitro. For clarity, ASR (Analyte Specific
      Reagent) products are included in the Field of Use.

     

    The
      term
“Valid
      Claim” means
      a
      claim in a pending or an issued, unexpired patent within the Rockefeller Patent
      Rights that (a) has not been finally cancelled, withdrawn, abandoned or rejected
      by any administrative agency or other body of competent jurisdiction, (b) has
      not been revoked, held invalid, or declared unpatentable or unenforceable in
      a
      decision of a court or other body of competent jurisdiction that is unappealable
      or unappealed within the time allowed for appeal, (c) has not been rendered
      unenforceable through disclaimer or otherwise, and (d) is not lost through
      an
      interference proceeding, provided, however, that any claim that has been pending
      for more than five (5) years after Company requests in writing that Rockefeller
      actively prosecute such claim (in the case of a claim to a specific micro RNA
      sequence by filing a divisional application specific to such sequence) shall
      cease to be a Valid Claim unless and until such claim is issued. 

     

    The
      term
“Diagnosis”
      means
      (a) the determination of (i) the presence of a disease, (ii) the stage,
      progression or severity of a disease, (iii) the risk of contracting a disease,
      or (iv) the effect on a disease of a particular treatment; and/or (b) the
      selection of patients for a particular treatment with respect to a
      disease.

     

    1.3  Reservation
      of Rights by Rockefeller.
      Rockefeller reserves the right to use, and to permit other entities to use,
      the
      Rockefeller Patent Rights for all purposes, provided however, that Rockefeller
      will not grant more than three (3) licenses (“Other Licenses”) to third parties
      to make, have made, use, have used, import, sell, have sold or offer for sale
      and have offered for sale Licensed Products in the Field of Use during the
      Term.

     

    1.4  U.S.
      Government Rights.
      The
      parties acknowledge that the United States government retains rights in
      intellectual property funded under any grant or similar contract with a Federal
      agency. The License is expressly subject to all applicable United States
      government rights, including, but not limited to, any applicable requirement
      that products, which result from such intellectual property and are sold in
      the
      United States, must be substantially manufactured in the United States. At
      the
      request of Company, and at Company’s expense, Rockefeller will assist Company in
      an effort to obtain a waiver of such requirement.

     

    1.5  Sublicenses.
      Licensee
      shall have no right to grant sublicenses under the license granted herein,
      unless such sublicense is granted as part of a license along with other
      substantial technology or patent rights of Licensee. Any such sublicense will
      be
      subject to each of the following conditions:

     

    (a)  In
      each
      sublicense agreement, Licensee will, (i) prohibit the sublicensee from further
      sublicensing, except for a further sublicense limited to the right to
      manufacture and distribute a Licensed Product developed by the sublicensee,
      and
      (ii) require the sublicensee to comply with the terms and conditions of this
      Agreement other than the payment and reporting obligations of
      Company.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    (b)  Within
      thirty (30) days after Licensee enters into a sublicense agreement, Company
      will
      deliver to Rockefeller a complete and accurate copy of the entire sublicense
      agreement written in the English language. Rockefeller’s receipt of the
      sublicense agreement, however, will constitute neither an approval of the
      sublicense nor a waiver of any right of Rockefeller or obligation of Company
      under this Agreement.

     

    (c)  In
      the
      event that Company causes or experiences a bankruptcy event, all payments due
      to
      Company from its Affiliates or sublicensees under the sublicense agreement
      will,
      upon notice from Rockefeller to such Affiliate or sublicensee, become payable
      directly to Rockefeller for the account of Company. Upon receipt of any such
      funds, Rockefeller will remit to Company the amount by which such payments
      exceed the amounts owed by Company to Rockefeller. 

     

    (d)  Company’s
      execution of a sublicense agreement will not relieve Company of any of its
      obligations under this Agreement. Company is primarily liable to Rockefeller
      for
      any act or omission of an Affiliate or sublicensee of Company that would be
      a
      breach of this Agreement if performed or omitted by Company, and Company will
      be
      deemed to be in breach of this Agreement as a result of such act or omission.
      

     

    2.  FEES
      AND ROYALTIES

     

    2.1  License
      Initiation Fee.
      In
      partial consideration of the License, Company will pay to Rockefeller on the
      Effective Date a non-refundable license initiation fee of [***] Dollars
      ($[***]). 

     

    2.2  License
      Maintenance Fees.
      In
      partial consideration of the License, Company will pay to Rockefeller, on each
      anniversary of the Effective Date, a license maintenance fee of [***] Dollars
      ($[***]). 

     

    2.3  Progress
      Report.
      In
      addition, Company shall provide Rockefeller on each anniversary of the Effective
      Date with written progress reports discussing the development, evaluation,
      testing and commercialization of all Licensed Products.

     

    2.4  Earned
      Royalties.
      In
      partial consideration of the License, subject to Sections 2.5 and 2.6, Company
      will pay to Rockefeller a royalty of (i) [***] Percent ([***]%) of Net Sales
      by
      Company and its Affiliates, and (ii) [***] Percent ([***]%) of all royalties
      received by the Company from sublicensees with respect to sales of Licensed
      Products, during each Quarter. 

     

    The
      term
“Quarter”
means
      each three-month period beginning on January 1, April 1, July 1 and October
      1.

     

    The
      term
“Net
      Sales”
means
      the consideration received from, or fair market value attributable to, each
      Sale, less Qualifying Costs directly attributable to a Sale and actually
      identified on the invoice and borne by Licensee or its sublicensees. Net sales
      shall not include sales or transfers between Company and its Affiliates, unless
      the Licensed Product is consumed by the Affiliate. For purposes of determining
      Net Sales, the words “fair market value” mean the cash consideration that
      Licensee or its sublicensees would realize from an unrelated buyer in an arms
      length sale of an identical item sold in the same quantity and at the time
      and
      place of the transaction. 

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    The
      term
“Sale”
means
      any bona fide transaction by Licensee or its sublicensees for which
      consideration is received or expected from an unaffiliated third party for
      the
      sale, use, lease, transfer or other disposition of a Licensed Product, and
      a
      Sale is deemed completed at the time that Licensee or its sublicensees invoices,
      ships or receives payment for a Licensed Product, whichever occurs
      first.

     

    The
      term
“Qualifying
      Costs”
means:
      (a) customary discounts in the trade for quantity purchased, prompt payment
      or
      wholesalers and distributors; (b) rebates (including Medicare and similar types
      of rebates), credits or refunds for claims or returns that do not exceed the
      original invoice amount; (c) prepaid outbound transportation expenses and
      transportation insurance premiums; and (d) sales and use taxes and other fees
      imposed by a governmental agency. 

     

    2.5  Stacking
      Protection.
      If
      Licensee becomes obligated to pay royalties to third parties for technology
      necessary to develop or manufacture a Licensed Product, then the royalty rate
      payable to Rockefeller under Section 2.4 for such Licensed Product will be
      reduced pro rata with respect to all third party royalty rates, so as to reduce
      the maximum aggregate royalty rate to [***]percent ([***]%). A reduction of
      the
      royalty rate in Section 2.4 for one Licensed Product will not affect the royalty
      rate for another Licensed Product. 

     

    2.6  Payments
      Related to Combination Products.
      In the
      event that a Licensed Product is sold in combination with another product or
      products, which are not a Licensed Products, the amount of royalties and
      payments paid shall be based on the proportion of the value of such combination
      product reasonably attributable to the Licensed Product. In particular, if
      a
      Licensed Product contains or is designed to detect both micro RNA sequences
      covered by a Valid Claim of Rockefeller Patent Rights and micro RNA sequences
      that are not covered by a Valid Claim of Rockefeller Patent Rights, then Net
      Sales of such Licensed Product shall be multiplied by the ratio of (x) the
      number of micro RNA sequences covered by a Valid Claim of Rockefeller Patent
      Rights in a given Licensed Product to (y) the total number of micro RNA
      sequences included in such given Licensed Product to determine the portion
      of
      the value of the micro RNA sequences in the combination product attributable
      to
      Rockefeller micro RNA sequences.

     

    2.7  Royalty
      Floor.
      Notwithstanding Sections 2.5 and 2.6, (i) in no event will the royalty rate
      payable to Rockefeller under Section 2.4 for any Licensed Product sold by
      Licensee be reduced to less than [***] percent ([***]%) of Net Sales, and (ii)
      in no event will the royalty payable to Rockefeller under Section 2.4 for any
      Licensed Product sold by a sublicensee be reduced to less than [***] percent
      ([***]%) of sublicensee Net Sales. 

     

    2.8  Sublicense
      Fees.
      In
      partial consideration of the License, Company will pay to Rockefeller a
      sublicense fee of [***] percent ([***]%) of all payments and the fair market
      value of all other consideration of any kind received by Company from
      sublicensees during the Quarter, other than: (a) equity investments in Company
      by a sublicense up to the amount of the fair market value of the equity
      purchased on the date of the investment; (b) loan proceeds paid to Company
      by a
      sublicensee in an arms length, full recourse debt financing; and (c) sponsored
      research funding paid to Company by a sublicensee in a bona fide transaction.
      Such sublicense fee sharing will be discountable in accordance with Section
      2.6,
      however, in no event will the sublicense fee be reduced to less than [***]
      percent ([***]%) of the consideration received by the Company from the
      sublicensee, except for royalties paid on sublicensee Sales which will be
      subject to the royalty floor in Section 2.7.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    2.9  Most
      Favored Licensee.
      If
      Rockefeller grants a license under the Rockefeller Patent Rights and which
      will
      permit such licensee to manufacture or sell for any use within the scope of
      the
      license granted in this Agreement at a lower royalty rate than that provided
      in
      this Agreement, then Rockefeller will promptly notify Company of such license.
      The notice will include all material terms and conditions of such license,
      including degree of non-exclusivity, duration, field, territory, audit rights,
      all fees, and royalty rates, and extend to Company the lower royalty rates
      along
      with all of the material terms and conditions of such license. In the event
      that
      Company elects to take the royalty rates and the material terms and conditions
      of such noticed license, the royalty rate and all material terms and conditions
      of such noticed license shall apply to Company upon the date Company provides
      Rockefeller with its written notice of such election.

     

    3.  REPORTS
      AND PAYMENTS

     

    3.1  Royalty
      Reports.
      Within
      sixty (60) days after the end of each Quarter following first commercial Sale
      of
      a Licensed Product, Company will deliver to Rockefeller a report, certified
      by
      the chief financial officer of company, detailing the calculation of all
      royalties and fees due to Rockefeller for such Quarter. The report will include,
      at a minimum: (a) the number of Licensed Products involved in Sales, listed
      by
      product, by country; (b) gross consideration invoiced, billed or received for
      Sales in the Quarter; (c) Qualifying Costs, listed by category of cost; (d)
      Net
      Sales, listed by product, by country; (e) royalties and fees owed to
      Rockefeller, listed by category, by product, by country; and (f) any applicable
      credits resulting from royalty credits.

     

    3.2  Payments.
      Company
      will pay all royalties due to Rockefeller under Section 2.4 within forty-five
      (45) days after the end of the Quarter in which the royalties or fees
      accrue.

     

    3.3  Records.
      Company
      will maintain, and cause its Affiliates and sublicensees to maintain, complete
      and accurate books and records to verify Sales, Net Sales, and all of the
      royalties, fees and other payments made under this Agreement. The records for
      each Quarter will be maintained for at least five (5) years after submission
      of
      the applicable report required under Section 3.1.

     

    3.4  Audit
      Rights.
      Upon
      reasonable prior written notice to Company, Company will provide an accountant
      selected by Rockefeller and approved by Company, such approval not to be
      unreasonably withheld, with access to all of the books and records required
      by
      Section 3.3 to conduct a review or audit of Sales, net Sales, Qualifying Costs
      (including the method of determining Qualifying Costs) and all of the royalties,
      fees, and other payments payable under this Agreement. Access will be made
      available: (a) during normal business hours; (b) in a manner reasonably designed
      to facilitate review or audit without unreasonable disruption to Company’s
      business; and (c) no more than once each calendar year during the Term and
      for a
      period of five (5) years thereafter. Company will promptly pay to Rockefeller
      the amount of any underpayment determined by the review or audit plus accrued
      interest. If the review or audit determines that Company has underpaid any
      royalty payment by [***] ([***]%) or more, then Company will also promptly
      pay
      the costs and expenses of Rockefeller and its accountants in connection with
      the
      review or audit.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    3.5  Information
      Rights.
      After
      the closing of the Company’s IPO, Company will provide to Rockefeller a copy of
      each annual report, proxy statement, 10-K, 10-Q and other material reports
      filed
      with the U.S. Securities and Exchange Commission.

     

    3.6  Currency.
      All
      dollar amounts referred to in this Agreement are expressed in United States
      dollars. All payments will be made in United States dollars. If Licensee
      receives payment from a third party in a currency other than United States
      dollars for which a royalty or fee is owed under this Agreement, then (a) the
      payment will be converted into United States dollars at the conversion rate
      for
      the foreign currency as published in the eastern edition of the Wall Street
      Journal as of the last business day of the Quarter in which the payment was
      received by Licensee, and (b) the conversion computation will be documented
      by
      Company in the applicable report delivered to Rockefeller under Section
      3.1.

     

    3.7  Place
      of Payment.
      All
      payments by Company are payable to “The Rockefeller University” and will be made
      to the following addresses:

     

    
      	
              By
                Electronic Transfer:

               

            	
              By
                Check:

               

            
	
              JP
                Morgan Chase Bank

            	
              The
                Rockefeller University

            
	
              1166
                Avenue of the Americas, 16th Floor

            	
              Office
                of Technology Transfer

            
	
              New
                York, NY 10036

            	
              502
                Founders Hall

            
	
              Swift
                Code: CHASUS33

            	
              1230
                York Avenue

            
	
              Account
                #134-756355

            	
              New
                York, NY 10021

            
	
              Reference:
                Technology Transfer/212-327-7116

            	 

    

     

    3.8  Interest.
      All
      amounts that are not paid by Company when due will accrue interest from the
      date
      due until paid at a rate equal to one percent (1.0%) per month (or the maximum
      allowed by law, if less).

     

    4.  CONFIDENTIALITY
      AND USE OF ROCKEFELLER’S
      NAME

     

    4.1  Rockefeller’s
      Confidential Information.
      The
      term “Confidential
      Information”
      includes all technical information, inventions, developments, discoveries,
      software, know-how, methods, techniques, formulae, data, processes and other
      proprietary ideas, whether or not patentable, that Rockefeller identifies as
      confidential or proprietary at the time it is delivered or communicated to
      Licensee or its sublicensees.

     

    4.2  Licensee’s
      Obligation.
      Licensee will maintain in confidence and not disclose to any third party any
      Confidential Information. Licensee will use the Confidential Information only
      for the purposes of this Agreement. Licensee will ensure that Licensee’s
      employees have access to the Confidential Information only on a need to know
      basis and are obligated in writing to abide by Licensee’s obligations under this
      Agreement. The obligations under this Section 4.2 will not apply to: (a)
      information that is known to Licensee or independently developed by Licensee
      prior to the time of disclosure, in each case where the Confidential Information
      is a specific micro RNA sequence, to the extent evidenced by written records
      promptly disclosed to Rockefeller upon receipt of the Confidential Information
      and in each other case, to the extent evidenced by written records that Company
      can demonstrate were in existence at the time of receipt of the Confidential
      Information; (b) information that is disclosed to Licensee by a third party
      that
      has a right to make such disclosure; (c) information that becomes patented,
      published or otherwise part of the public domain as a result of acts by
      Rockefeller or a third party obtaining such information as a matter of right;
      or
      (d) information that is required to be disclosed by order of United States
      governmental authority or a court of competent jurisdiction provided that
      Licensee must use its best efforts to obtain confidential treatment of such
      information by such agency or court.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    4.3  Disclaimer.
      Rockefeller is not obligated to accept any confidential information from
      Licensee, except for the reports required by Sections 2.3, 3.1 and 3.5.
      Rockefeller, acting through its Office of Technology Transfer and finance
      offices, will use its best efforts not to disclose to any third party outside
      of
      Rockefeller any confidential information of Licensee contained in those reports,
      subject to exceptions analogous to those contained in Section 4.2(a) - (d)
      above. Rockefeller bears no institutional responsibility for maintaining the
      confidentiality of any other information of Licensee. Licensee may elect to
      enter into confidentiality agreements with individual investigators at
      Rockefeller that comply with Rockefeller’s internal policies.

     

    4.4  Use
      of
      Rockefeller’s Name.
      Licensee, its sublicensees and their employees and agents may not use the name,
      logo, seal, trademark or service mark (including any adaptation of them) of
      Rockefeller or any Rockefeller school, organization, employee, student or
      representative, without the prior written consent of Rockefeller.

     

    5.  TERM
      AND TERMINATION

     

    5.1  Term.
      This
      Agreement will commence on Effective Date and terminate upon the later of:
      (a)
      the expiration or abandonment of the last patent to expire or become abandoned
      of the Rockefeller Patent Rights; or (b) if no patent ever issues from the
      Rockefeller Patent Rights, ten (10) years after the first commercial sale of
      the
      first Licensed Product (as the case may be the “Term”).

     

    5.2  Early
      Termination by Company.
      Company
      may terminate this Agreement at any time upon sixty (60) days prior written
      notice to Rockefeller after completing each of the following: (a) ceasing to
      make, have made use, import, sell and offer for sale all Licensed Products;
      (b)
      terminating all sublicenses and causing all Affiliates and sublicenses to cease
      making, having made, using, importing, selling and offering for sale all
      Licensed Products; and (c) paying all amounts owed to Rockefeller under this
      Agreement through the date of termination.

     

    5.3  Early
      Termination by Rockefeller.
      Rockefeller may terminate this Agreement if: (a) Company is more than thirty
      (30) days late in paying to Rockefeller any amounts owned under this Agreement
      and does not immediately pay Rockefeller in full within ten (10) days after
      demand; or (b) Company or its Affiliates or sublicensees breaches this Agreement
      and does not cure the breach within forty-five (45) days after written notice
      of
      the breach.

     

    5.4  Effect
      of Termination.
      Upon
      the termination of this Agreement for any reason: (a) the License terminates;
      (b) Licensee and its sublicensees will cease all making, having made, using,
      importing, selling and offer for sale all Licensed Products; (c) Company will
      pay to Rockefeller all amounts owned to Rockefeller through the date of
      termination under this Agreement; (d) Licensee will, at Rockefeller’s request,
      return to Rockefeller all Confidential Information; and (e) in the case of
      termination under Section 5.3, all duties of Rockefeller and all rights (but
      not
      duties) of Licensee under this Agreement immediately terminate without further
      action required by either Rockefeller or Licensee.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    5.5  Survival.
      Company’s obligation to pay all amounts owned to Rockefeller under this
      Agreement will survive the termination of this Agreement for any reason.
      Articles 4, 5, 8, 9 and Section 11.10 will survive the termination of this
      Agreement for any reason in accordance with their respective terms.

     

    6.  PATENT
      MAINTENANCE AND REIMBURSEMENT

     

    6.1  Patent
      Maintenance.
      Rockefeller controls the preparation, prosecution and maintenance of the
      Rockefeller Patent Rights and the selection of patent counsel, with input from
      Company. Company will be copied on, and allowed to comment upon, all substantive
      issues in the patent prosecution.

     

    6.2  Patent
      Reimbursement.
      Within
      thirty (30) days after the Effective Date, Company shall reimburse Rockefeller
      $[***] for a pro rata share of patent and licensing costs incurred prior to
      the
      Effective Date. Company shall pay a pro rata share (based on the number of
      licenses granted to the Rockefeller Patent Rights), not to exceed [***]%, for
      all attorney fees, expenses, official fees and other charges incident to the
      preparation, prosecution, and maintenance of such patent applications and
      patents following the Effective Date.

     

    7.  INFRINGEMENT

     

    7.1  Notice.
      Company
      and Rockefeller will notify each other promptly of any infringement of the
      Rockefeller Patent Rights that may come to their attention. Company and
      Rockefeller will consult each other in a timely manner concerning any
      appropriate response to the infringement.

     

    7.2  Prosecution.
      Rockefeller may prosecute any infringement of the Rockefeller Patent Rights
      at
      Rockefeller’s expense. If Rockefeller elects to prosecute such infringement,
      then financial recoveries will retained by Rockefeller in their
      entirety.

     

    7.3  Intervention.
      Rockefeller reserves the right to request Company to join in any litigation
      under Section 7.2 If Company elects to participate in any such litigation,
      then
      financial recoveries from any such litigation will be shared between Company
      and
      Rockefeller in proportion with their respective shares of the aggregate
      litigation expenditures.

     

    7.4  Company
      Prosecution.
      If
      Rockefeller does no prosecute any infringement of the Rockefeller Patent Rights,
      Company may prosecute any infringement of the Rockefeller patent Rights at
      Company’s expense. Company must not settle or compromise any such litigation in
      a manner that imposes any obligations or restrictions on Rockefeller or grants
      any rights to the Rockefeller Patent Rights without Rockefeller’s prior written
      permission. Financial recoveries from any such litigation will be: (a) first,
      applied to reimburse Company for its litigation expenditures; and (b) second,
      as
      to any remainder, retained by Company, but treated as Net Sales for the purpose
      of determining the royalties due to Rockefeller under Section 2.4.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    7.5  Cooperation.
      In any
      litigation under this Article 7, either party, at the request and expense of
      the
      other party, will cooperate to the fullest extent reasonably possible. This
      Section 7.5 will not be construed to require either party to undertake any
      activities, including legal discovery, at the request of any third party, except
      as may be required by lawful process of a court of competent
      jurisdiction.

     

    8.  REPRESENTATIONS;
      DISCLAIMER OF WARRANTIES; LIMITATION OF LIABILITIES

     

    8.1  Rockefeller
      and Company each represent that, to the best of their knowledge as of the
      Effective Date, they have the legal right and authority to enter into this
      Agreement and to perform all obligations hereunder. Rockefeller further
      represents that, to the best of the knowledge of the Office of Technology
      Transfer as of the Effective Date, the patent applications listed on Exhibit
      A
      have been assigned to Rockefeller by the inventors named therein and Rockefeller
      owns all right title and interest of such inventors in such patent
      applications.

     

    8.2  THE
      ROCKEFELLER PATENT RIGHTS, ROCKEFELLER TECHNICAL INFORMATION, LICENSED PRODUCTs,
      AND ANY OTHER TECHNOLOGY LICENSED UNDER THIS AGREEMENT ARE PROVIDED ON AN “AS
      IS” BASIS. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, ROCKEFELLER MAKES NO
      REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED
      TO
      ANY WARRANTY OF ACCURACY, COMPLETENESS, PERFORMANCE, MECHANTABILITY, FITNESS
      FOR
      A PARTICULAR PURPOSE, COMMERCIAL UTILITY, NON-INFRINGEMENT OR TITLE. ROCKEFELLER
      WILL NOT BE LIABLE TO LICENSEE, ITS SUCCESSORS, OR ASSIGNS, OR ANY THIRD PARTY
      WITH RESPECT TO ANY CLAIM: ARISING FROM LICENSEE’S USE OF THE ROCKEFELLER PATENT
      RIGHTS, ROCKEFELLER TECHNICAL INORMATION, LICENSED PRODUCTS OR ANY OTHER
      TECHNOLOGY LICENSED UNDER THIS AGREEMENT; ARISING FROM THE DEVELOPMENT, TESTING,
      MANUFACTURE, USE OR SALE OF LICENSED PRODUCTS; OR FOR LOST PROFITS, BUSINESS
      INTERRUPTION, OR INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES OF ANY
      KIND.

     

    9.  INDEMNIFICATION

     

    9.1  Indemnification.
      Company
      will defend, indemnify, and hold harmless Rockefeller, and its trustees,
      officers, faculty, agent, employees, and students (each, an “Indemnified Party”)
      from and against any and all liability, loss, damage, action, claim or expense
      including attorneys’ fees and expenses suffered or incurred by the Indemnified
      Parties (collectively “Liabilities”), arising out of or resulting from (a) the
      development, testing, use, manufacture, promotion, sale or other disposition
      of
      any Rockefeller Patent Rights or Licensed Products by Licensee, sublicensees,
      vendors or third parties; (b) any material breach of this Agreement by Licensee
      or its sublicensees; and (c) the enforcement of this Article 9 by any
      Indemnified Party. Liabilities include, but are not limited to: (x) any product
      liability or other claim of any kind related to use by a third party of a
      Licensed Product that was manufactured, sold or otherwise disposed of by
      Licensee, sublicensees, vendors or third parties; (y) a claim by a third party
      that the Rockefeller Patent Rights or the design, composition, manufacture,
      use,
      sale or other disposition of any Licensed Product infringes or violates any
      patent, copyright, trade secret, trademark or other intellectual property right
      of such third party; and (z) clinical trials or studies conducted by or on
      behalf of Licensee, its sublicensees, assignees or vendors or third parties
      relating to the Rockefeller Patent Rights or the Licensed Products, such as
      claims by or on behalf of a human subject of any such trial or
      study.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    9.2  An
      Indemnified Party entitled to be indemnified pursuant to 9.1 shall promptly
      notify the Company in writing, of any claim or demand with reasonable
      specificity, which the Indemnified Party has determined has given or is
      reasonably likely to give rise to a right of indemnification under this
      Agreement within 45 days of such determination; provided, however, that a
      failure to provide such notice shall not relieve any Indemnifying Party of
      its
      obligations hereunder except to the extent that it has been materially
      prejudiced by such failure. If the Indemnified Party shall notify the
      Indemnifying Party of any claim or demand pursuant to this Section 9.2, and
      if
      such claim or demand relates to a claim or demand asserted by a third party
      against the Indemnified Party that the Company acknowledges is a claim or demand
      for which it must indemnify or hold harmless the Indemnified Party, the Company
      shall have the right to employ counsel of its choice to defend any such claim
      or
      demand asserted against the Indemnified Party provided that the Indemnifying
      Party provides the Indemnified Party with a copy of the claim, answer to the
      claim, periodic updates (including papers filed or served) as requested by
      the
      Indemnified Party an opportunity to review documents to be served and/or to
      be
      filed on behalf of the Indemnified Party with adequate time to allow the
      Indemnified Party sufficient opportunity for review and comment before such
      documents are served and/or filed and the final papers resolving the matter.
      The
      Indemnified Party shall have the right to employ counsel of its choice in the
      defense of any such claim or demand at its own expense. The Company shall notify
      the Indemnified Party in writing, as promptly as possible (but in any case
      ten
      (10) business days before the due date for the answer or response to a claim)
      after the date of the notice of claim given by the Indemnified Party to the
      Company under this Section 9.2, of its election to defend in good faith any
      such
      third party claim or demand. So long as the Company is defending in good faith
      any such claim or demand asserted by a third party against the Indemnified
      Party, the Indemnified Party shall not settle or compromise such claim or demand
      without the Indemnifying Party’s approval. The Indemnified Party shall make
      available to the Company or its agents, at the Company’s cost, all relevant
      records and other material in the Indemnified Party’s possession relating to any
      third party claim or demand.

     

    9.3  Other
      Provisions.
      Company
      will not settle or compromise any claim or action giving rise to Liabilities
      in
      any manner that imposes any restrictions on obligations on Rockefeller or grants
      any rights to the Rockefeller Patent Rights or the Licensed Products without
      Rockefeller’s prior written consent. If Company fails or declines to assume the
      defense of any claim or action within thirty (30) days after notice of the
      claim
      or action and does not notify Rockefeller that it disputes the right to
      indemnification, then Rockefeller may assume the defense of such claim or action
      for the account and at the risk of the Company, and any Liabilities related
      to
      such claim or action will be conclusively deemed a liability of Company. The
      indemnification rights of the Indemnified Parties under this Article 9 are
      in
      addition to all other rights that an Indemnified Party may have at law, in
      equity or otherwise.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    10.  INSURANCE

     

    10.1  Coverages.
      Company
      will procure and maintain insurance policies for the following coverages with
      respect to personal injury, bodily injury and property damage arising out of
      Company’s performance under this Agreement: (a) during the Term, comprehensive
      general liability, including broad form and contractual liability, in a minimum
      amount of $[***] combined single limit per occurrence and in the aggregate;
      and
      (b) prior to the sale of the first Licensed Product, product liability coverage,
      in a minimum amount of $[***] combined single limit per occurrence and in the
      aggregate. The required minimum amounts of insurance do not constitute a
      limitation on Company’s liability or indemnification obligations to Rockefeller
      under this Agreement.

     

    10.2  Other
      Requirements.
      The
      policies of insurance required by Section 10.1 will be issued by an insurance
      carrier with an A.M. Best rating of “A” or better and will name Rockefeller as
      an additional insured with respect to Company’s performance under this
      Agreement. Company will provide Rockefeller with insurance certificates
      evidencing the required coverage within thirty (30) days after the commencement
      of each policy period and any renewal periods. Each certificate will provide
      that the insurance carrier will notify Rockefeller in writing at least thirty
      (30) days prior to the cancellation or material change in coverage.

     

    11.  ADDITIONAL
      PROVISIONS

     

    11.1  Independent
      Contractors.
      The
      parties are independent contractors. Nothing contained in this Agreement is
      intended to create an agency, partnership, or joint venture between the parties.
      At no time will either party make commitments or incur any charges or expenses
      for or on behalf of the other party.

     

    11.2  No
      Discrimination.
      Neither
      Rockefeller nor Licensee will discriminate against any employee or applicant
      for
      employment because of race, color, sex, sexual or affectional preference, age,
      religion, national or ethnic origin, handicap or veteran status.

     

    11.3  Compliance
      with Laws.
      Licensee must comply with all prevailing laws, rules and regulations that apply
      to its activities or obligations under this Agreement. For example, Licensee
      will comply with applicable United States export laws and regulations. The
      transfer of certain technical data and commodities may require a license from
      the applicable agency of the United States government and/or written assurances
      by Licensee that Licensee will not export data or commodities to certain foreign
      countries without prior approval of the agency. Rockefeller does not represent
      that no license is required, or that, if required, the license will
      issue.

     

    11.4  Modification,
      Waiver and Remedies.
      This
      Agreement may only be modified by a written amendment that is executed by an
      authorized representative of each party. Any waiver must be express and in
      writing. No waiver by either party of a breach by the other party will
      constitute a waiver of any different or succeeding breach. Unless otherwise
      specified, all remedies are cumulative.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    11.5  Assignment.
      Company
      many not assign this Agreement or any part of it, either directly or by merger
      or operation of law, without the prior written consent of Rockefeller, except
      that Company may assign this Agreement and the rights, obligations and interests
      of Company, in whole, to any of its Affiliates, to any purchase of all of its
      capital stock or assets or to any successor corporation resulting from any
      merger or consolidation of company with or into such corporation; each of which
      will agree in writing to be legally bound this Agreement. Rockefeller will
      not
      unreasonably withhold or delay its consent, provided that: (a) at least thirty
      (30) days before the proposed transaction, Company gives Rockefeller written
      notice and such background information as may be reasonably necessary to enable
      Rockefeller to give an informed consent; (b) the assignee agrees in writing
      to
      be legally bound by this Agreement; and (c) the assignee agrees to deliver
      to
      Rockefeller an updated Progress Report within forty-five (45) days after the
      closing of the proposed transaction. Any permitted assignment will not relieve
      Company of responsibility for performance of any obligation of Company that
      has
      accrued at the time of the assignment. Any prohibited assignment will be null
      and void.

     

    11.6  Notices.
      Any
      notice or other required communication (each, a “Notice”)
      must
      be in writing, addressed to the party’s respective Notice Address listed on the
      signature page, and delivered: (a) personally; (b) by certified mail, postage
      prepaid, return receipt requested; (c) by recognized overnight courier service
      providing evidence of delivery, charges prepaid; or (d) by facsimile. A Notice
      will be deemed received: if delivered personally, on the date of delivery;
      if
      mailed, five (5) days after deposit in the United States mail; if sent via
      courier, one (1) business day after deposit with the courier service; or if
      sent
      via facsimile, upon receipt of confirmation of transmission provided that a
      confirming copy of such Notice is sent by certified mail, postage prepaid,
      return receipt requested or by courier as set forth above.

     

    11.7  Severability
      and Reformation.
      If any
      provision of this Agreement is held to be invalid or unenforceable by a court
      of
      competent jurisdiction, then the remaining provisions of this Agreement will
      remain in full force and effect. Such invalid or unenforceable provision will
      be
      automatically revised to be a valid or enforceable provision that comes as
      close
      as permitted by law to the parties’ original intent.

     

    11.8  Headings
      and Counterparts.
      The
      headings of the articles and sections included in this Agreement are inserted
      for convenience only and are not intended to affect the meaning or
      interpretation of this Agreement. This Agreement may be executed in several
      counterparts, all of which taken together will constitute the same
      instrument.

     

    11.9  Governing
      Law.
      This
      Agreement will be governed in accordance with the law of the State of New York,
      without giving effect to the conflict of law provisions of any
      jurisdiction.

     

    11.10  Dispute
      Resolution.
      If a
      dispute arises between the parties concerning any right or duty under this
      Agreement, then the parties will confer, as soon as practicable, in an attempt
      to resolve the dispute. If the parties are unable to resolve the dispute
      amicably, then the parties will submit to the exclusive jurisdiction of, and
      venue in, the state and Federal courts located in the State of New York with
      respect to all disputes arising under this Agreement.

     

    11.11  Integration.
      This
      Agreement, together with all attached Exhibits contain the entire agreement
      between the parties with respect to the Rockefeller Patent Rights and the
      License and supersede all other oral or written representations, statements,
      or
      agreements with respect to such subject matter, including but not limited to
      any
      term sheet.

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    Each
      party has caused this Agreement to be executed by its duly authorized
      representative.

     

    
      	
              THE
                ROCKEFELLER UNIVERSITY

            	
              ROSETTA
                GENOMICS

            
	 	 
	 	 
	
              By:
                

            	/s/ John
              Tooze                                  
              	
              By:

            	
              /s/
                Amir
                Avniel               
                

            
	
              Name:
                

            	John Tooze	
              Name:

            	
              Amir
                Avniel

            
	
              Title:
                

            	Vice President	
              Title:

            	
              President
                and COO

            
	
            	
              Scientific
                and Facility Operations

            	 	
              Rosetta
                Genomics, LTD.

            

    

     

    
 

    
      	
              Address:

            	
              Address:

            
	 	 
	
              The
                Rockefeller University

            	
              Rosetta
                Genomics Inc.

            
	
              Office
                of Technology Transfer

            	
              675
                US Highway One

            
	
              1230
                York Avenue, Box 81

            	
              Suite
                B119

            
	
              New
                York, NY 10021

            	
              North
                Brunswick, NJ 08902

            
	 	 
	
              Required
                copy to:

            	 
	 	 
	
              The
                Rockefeller University

            	
              Mintz
                Levin Cohn Ferris

            
	
              Office
                of General Counsel

            	
              Glovsky
                and Popeo, PC

            
	
              1230
                York Avenue, Box 81

            	
              One
                Financial Center

            
	
              New
                York, NY 10021

            	
              Boston,
                MA 02111

            
	 	
              Attn:
                Jeffrey Wiesen

            

    

     

    
 

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    EXHIBIT
      A

    Rockefeller
      Patent Rights and Sequences Represented

     

    

      
        	 	 	 	 	 	 	 	 	 
	s 	
                [***]

              	 	 	 	 	 	 	 
	 	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
              
	 	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

      

    

     

    

      11
        sequences

    

     

    
      

        
          	 	 	 	 	 	 	 	 	 
	s 	
                  [***]

                	 	 	 	 	 	 	 
	 	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                
	 	
                   

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

      
 

    

    
      
        
          	 	11
                  [***]
                  sequences	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	 
	 	
                   

                	
                  [***]

                	
                  [***]

                	
                  
                    [***]

                  

                	
                	
                   

                	
                	
                
	 	
                  
                    [***]

                  

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

       

    

    
      

        
          	 	15
                  [***]
                  sequences	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                	 

        

      

       

    

    
      
        

          
            	 	5
                    [***]
                    sequences	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	s 	
                    [***]

                  	
                    [***]

                  	
                    [***]

                  	
                    [***]

                  	
                    [***]

                  	
                    [***]

                  	
                  	 

          

           

        

      

    

    
      
        
          	 	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                
	 	
                   

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                	
                  [***]

                

        

      

      
        	
              	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

        	
              	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

        	
              	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

        	
              	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

        	
              	
                
                  [***]

                

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

        	
              	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

        	
              	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

        	
              	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

        	
              	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

        	
              	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

        	
              	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

      

    

    
      	
            	
               

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            

      	
            	
               

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            

      	
            	
               

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            

      	
            	
               

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            

    

     

     

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
            	
               

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            

      	
            	
               

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            

      	
            	
               

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            

      	
            	
               

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            

      	
            	
               

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            

      
        	
              	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

        	
              	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

        	
              	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

        	
              	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

      

      
        	
              	
                 

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              	
                [***]

              

      

    

    
      	
            	
               

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
              [***]

            	
            	
               

            

    

     

    

      130
        Sequences

       

    

    
      	s 	
              [***]

            	
               

            	
            	
            	
            	
            	
            	 

       

      
        
          
            	 	
                    [***]

                  	
                    [***]

                  	
                    [***]

                  	
                    [***]

                  	
                    [***]

                  	
                    [***]

                  	
                    [***]

                  	
                  

          

        

        
        

      

    

     

    
 

    
      
        Portions
          of this Exhibit were omitted and have been filed separately with the Secretary
          of the Commission pursuant to the Company’s application requesting confidential
          treatment under Rule 406 of the Securities Act.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}]]